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ABSTRACT 
Much effort has been devoted to understanding the molecular mechanisms 
involved in the pathogenesis and progression of advanced thyroid cancer.  However, 
little progress has been made in the development of effective therapeutic 
interventions. Single-agent therapies targeting known oncogenic drivers have had 
limited clinical efficacy thus far, and as such, novel therapeutic targets and upfront 
combinations need to be identified. This work finds focal adhesion kinase (FAK), 
containing both scaffolding and kinase functions, to be a novel therapeutic target for 
advanced thyroid cancer and provides a rational, upfront combination strategy to 
increase the efficacy of FAK-directed therapies.  
First, using genetic and pharmacological approaches both in vitro and in vivo, 
I provide evidence that FAK mediates pro-tumorigenic processes in thyroid cancer. 
Knockdown of FAK decreases cell viability, anchorage-independent growth, invasion, 
tumor growth, and metastasis. Using an inhibitor which blocks FAK kinase activity, but 
not scaffolding function, I further demonstrate that the kinase activity of FAK is 
dispensable, having only minimal effects on cell survival, invasion, tumor growth, and 
metastasis. Taken together, the scaffolding activity of FAK is the key function in FAK-
mediated processes, and targeting the scaffolding function(s) of FAK in thyroid cancer 





Second, I demonstrate that chronic treatment with a Src inhibitor in BRAF-
mutant thyroid cancer promotes a key switch in FAK function from scaffolding to 
kinase activity. This functional switch in FAK promotes increased reliance on a 
p130Cas/c-JUN signaling module and drives acquisition of an invasive-phenotype. 
This work identifies a rational, upfront combination therapy, which targets the kinase 
activity of both FAK and Src to increase therapeutic efficacy of the single-agents. This 
may provide a therapeutic advantage by inhibiting both the proliferative and invasive 
populations, which can mediate drug resistance and cancer recurrence.  
Overall, these pre-clinical studies provide evidence of the complexity of FAK 
signaling and provides therapeutic strategies that may inhibit both cancer proliferation 
and invasion, to ultimately improve the survival of patients with advanced thyroid 
cancer, as well as other patients with FAK-dependent tumors.  
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Normal Thyroid Anatomy and Pathology 
The thyroid is a butterfly-shaped gland that sits low on the front of the 
larynx and trachea. The thyroid has two side lobes, connected by a central 
bridge, the isthmus (1). There are three main cellular features of the thyroid – 
follicles, follicular cells, and parafollicular C cells. Thyroid follicles are small 
spherical groupings of cells that surround a core of colloid which consists of the 
thyroid hormone precursor protein, thyroglobulin, an iodinated glycoprotein. The 
core of the follicle is surrounded by a single layer of follicular cells and scattered 
among the follicular cells and follicles, lie the parafollicular C cells (1).  
 The primary function of the thyroid is to produce the iodine-containing 
thyroid hormones, triiodothyronine (T3) and thyroxine (T4), as well as to produce 
the peptide hormone calcitonin (2). Hormone output from the thyroid is regulated 
by thyroid-stimulating hormone (TSH) secreted from the anterior pituitary, which 
itself is regulated by thyrotropin-releasing hormone produced by the 
hypothalamus (1). When the follicular cells are stimulated by TSH, thyroglobulin 
is absorbed from the follicular space, the iodinated tyrosines of the protein are 
cleaved, and T3 and T4 are formed (2). Thyroid hormones affect a variety of 
body functions including metabolism, blood flow and body temperature, as well 






Thyroid Cancer Statistics and Histological Classifications 
 Thyroid cancer is the most common endocrine malignancy, accounting for 
~4% of new cancer cases diagnosed in 2016 (3). However, the rate of incidence 
has been increasing over the past 10 years and it is predicted that thyroid cancer 
will surpass both colon cancer and melanoma diagnoses by the year 2030 (4). 
While this rise has been attributed to increased diagnosis, as access to high-
resolution imaging techniques is more readily available, other explanations, such 
as environmental factors, are also currently being investigated (5). Each year 
approximately 57,000 new cases of thyroid cancer are diagnosed and 2,000 
patients will succumb to their disease. Although the death rates for thyroid cancer 
are low, the rate of disease recurrence is high and this correlates with patient 
mortality, most commonly due to extrathyroidal invasion and distant metastasis 
(6).  
The thyroid gland gives rise to diverse types of cancers that differ in 
molecular profile, morphology, and tumorigenicity. Based on histopathological 
characteristics, thyroid cancer can be divided into four subtypes: medullary, 
papillary, follicular, and anaplastic (7).  
Medullary thyroid carcinomas (MTC) arise from the parafollicular C cells 
and accounts for 3-4% of all diagnosed thyroid cancers (6). MTC pathogenesis 
can be both sporadic and hereditary, with sporadic forms being the most 
common (70%) (8). The primary underlying mechanism for MTC tumorigenesis is 
activating mutations in the receptor tyrosine kinase RET, which promotes 





is 86% (9). This discussion on MTC has been included for completeness, but as 
the focus of this thesis is on signaling mechanisms in advanced thyroid cancers 
of follicular origin, the remainder of this introduction will focus on these 
classifications of tumors.  
Most thyroid cancer, including the papillary (PTC), follicular (FTC), and 
anaplastic (ATC) thyroid carcinomas subtypes, arise from the follicular cells. 
Approximately 80-85% of all thyroid cancer are papillary – named as such 
because the tumor cells form finger-like or papillary structures (10). Genetically, 
PTC tumors have one of the quietest cancer genomes, with very few copy 
number alterations or point mutations, which correlates with clinical indolence  
that is commonly observed (11).  
The second more frequent subtype is follicular thyroid cancer, which 
comprises about 10-15% of all thyroid cancers. Papillary and follicular thyroid 
cancers are well differentiated thyroid cancers (DTC) that still display some or all 
of the characteristics of mature thyroid tissue (12). These cancer subtypes, when 
detected early, have excellent prognoses with almost 100% survival at 5 years. 
However, even after standard of care, recurrence occurs in up to 40% of 
patients, which correlates with increased dedifferentiation and aggressive 
phenotypes (8).  
The remaining 1-2% of thyroid cancers are anaplastic in nature. ATC 
tumors generally arise as a progression from the more differentiated subtypes of 
follicular origin, including PTC and FTC (11). ATC cancers are highly malignant 





(10). Unfortunately, diagnosis of ATC does not usually occur until the disease 
has already reached an advanced stage, as characterized by extensive invasion 
and metastasis to distant organs. As such, ATC is very lethal with a median 
survival rate of only 4 months, and ~95% of patients will die within 6 months of 
diagnosis (7). Indeed, ATC remains one of the deadliest types of cancer overall.  
 
Molecular Events Governing Disease Pathogenesis 
 Advances in molecular biology have tremendously improved our 
understanding of the underlying mechanisms of thyroid cancer initiation and 
progression. At the core of thyroid cancer pathogenesis are 2 classical signaling 
pathways, the mitogen-activated protein kinase (MAPK) and the 
phosphatidylinositol 3-kinase (PI3K)/AKT pathway. Each pathway is key in 
regulating cell proliferation, survival, and tumorigenesis (Figure 1.1) (13). The 
importance of these pathways has been demonstrated in thyroid, as well as other 
cancer types. In thyroid cancer, MAPK pathway is driven by activating mutations 
in RAS, BRAF, and through RET/PTC rearrangements (6).  These mutations are 
mutually exclusive and are the primary drivers of the PTC and FTC subtypes. 
Additional mutations, such as those in components that regulate the PI3K/AKT 
pathway, likely mediate the progression of these differentiated thyroid cancers 






In addition to these well-known activators, both MAPK- and PI3K/AKT-mediated 
tumorigenesis is affected by input from extracellular signals, deregulation of 
tyrosine kinase and G-protein-coupled receptors, as well as input from other 
signaling pathways (6). While these factors can all contribute to MAPK and 
Figure 1.1: Pathways commonly deregulated in thyroid cancer. 
Activation of the MAPK pathway by oncogenic stimuli such as mutated BRAF, 
RAS or the chimeric fusion proteins RET/PTC is a common tumor initiating 
event in well differentiated papillary carcinoma and in some follicular 
carcinomas. Mutations involving the effectors of the PI3K/AKT pathway such 
as the PI3K subunit PIK3CA, and AKT1, and PTEN deletions are found more 
frequently in follicular carcinomas and in less differentiated types of thyroid 
cancer, including anaplastic carcinomas. Asterisks denote common 
mutations in thyroid cancer that potentiate signaling of the pathway(s).  






PI3K/AKT pathway activation in cancer, to provide the most appropriate 
background for this thesis, the following discussion will only include the most 
prevalent oncogenic drivers currently identified in PTC and ATC subtypes: RAS, 
BRAF, RET/PTC, and PI3K/AKT.  
RAS genes encode intracellular G-proteins that locate to the cell 
membrane upon activation by tyrosine kinase and G-protein-coupled receptors 
and function to convert guanosine diphosphate (GDP) to guanosine triphosphate 
Figure 1.2: Thyroid cancer pathogenesis and molecular mutations. 
RET/PTC rearrangements and BRAF and RAS activating mutations are 
involved in initiation and progression of normal follicular cells into PTC. RAS 
activating mutations are involved in FTC initiation and progression. 
Dedifferentiation of PTC and FTC involves activation of mediators of the 
PI3K/AKT pathway, including PI3KCA and AKT, or deletion of the tumor 
suppressor protein PTEN. Transitions to completely dedifferentiated ATC 
subtype involves p53 mutations. Conversely, activating mutations in the 
proto-oncogene RET are involved in the formation of all familial medullary 
thyroid carcinomas and subset of the sporadic subtype.  Adapted from Xing 






(GTP) using intrinsic enzymatic capacities (14). There are three isoforms of RAS: 
HRAS, KRAS, and the most predominantly mutated isoform in thyroid cancer, 
NRAS (6). Point mutations in codon 12 or 13 of the RAS gene results in an 
increased affinity for GTP while mutations in codon 61 inactivates the 
autocatalytic GTPase function of the protein (6). Both mutation types render the 
protein permanently active, allowing for constitutive signaling to downstream 
pathways including both MAPK and PI3K/AKT (Figure 1.1). RAS mutations are 
present in 15% of PTC and 24% of ATC tumors, and have been reported to be 
associated with a more aggressive behavior and higher frequency of distant 
metastases (11,14).  
BRAF is a serine-threonine kinase that belongs to the family of RAF 
proteins, which are intracellular effectors of the MAPK signaling cascade. RAS 
binding and protein recruitment triggers BRAF activation, which phosphorylates 
and activates MEK, subsequently activating ERK and effectors of the MAPK 
pathway (Figure 1.1). Point mutations in BRAF are found in ~60% of PTCs and 
45% of ATCs, and almost all of those mutations result in a valine-to-glutamate 
substitution at residue 600 on nucleotide 1799 (V600E; T1799A). The V600E 
mutation disrupts auto-inhibitory interactions between the activation loop and 
adenosine triphosphate (ATP) binding site on BRAF, which allows the protein to 
remain in the catalytically active form. Therefore, the V600E mutation results in a 
constitutively active form of BRAF that promotes MAPK signaling even in the 





aggressive tumor characteristics including local tumor invasion, tumor 
recurrence, and distant metastases (14).  
 RET is a tyrosine kinase receptor primarily expressed in cells derived from 
the neural crest, including the parafollicular C cells of the thyroid (10). RET can 
be aberrantly activated through chromosomal recombination where the γ’ portion 
of the RET gene, the intracellular tyrosine kinase domain, is coupled to the 5’ 
portion of various genes. In PTC, RET is fused to the H4 gene giving rise to the 
RET/PTC oncoprotein (14). The intact tyrosine kinase domain of RET/PTC 
oncoprotein promotes adaptor protein binding and activation of both MAPK and 
PI3K/AKT (Figure 1.1) (6). RET rearrangements are present in sporadic PTCs 
and have been linked to radiation exposure, but RET mutations are not restricted 
to malignant phenotypes as they have also been identified in benign samples 
(10). However, thyroid-specific expression of RET/PTC fusions in transgenic 
mice leads to the development of PTC, and were characterized as slow growing 
and non-metastatic (10).  
Activating mutations in the PIK3CA gene, which encodes the catalytic 
subunit of PI3K, have been widely reported in human cancers and are common 
in thyroid cancer, with mutations most often occurring in exon 9 and exon 20. 
PTEN, a tumor suppressor and important negative regulator of the PI3K/AKT 
pathway, can be mutated but, is most often deleted in advanced and aggressive 
thyroid cancer. Copy number gains are common for genes encoding PI3K/AKT 
pathways members including PIK3CA, PIK3CB, 3-phosphoinositide-dependent 





genetic alterations and copy-number gains in components of the PI3K/AKT 
pathway are more prevalent in ATC than PTC, in the range of 10-50% of ATC 
tumors, suggesting that these alterations are important for thyroid cancer 
dedifferentiation, progression, and aggressiveness (Figure 1.2) (6,11).  
 
Current Diagnostic and Therapeutic Modalities  
Thyroid cancer is commonly diagnosed during routine physical 
examinations. At presentation, patients will usually be symptomless but will have 
a palpable thyroid nodule or a nodule incidentally found on an imaging scan (15). 
Currently, fine-needle aspiration cytology, followed by an additional core biopsy if 
necessary, is the most used tool for diagnosis, which dictates therapy regimens 
(12). Patients with well-differentiated thyroid cancers, including PTC and FTC, 
will be treated with either surgery alone, or a combination of surgery, radioactive 
iodine therapy, and suppression therapy with thyroid hormone (15). Unfortunately 
for patients with advanced thyroid cancers including ATC, neither surgery nor 
radioiodine therapy is useful, due to increased local invasion, distant metastasis, 
and the loss of sensitivity to radioiodine treatment. However, the majority of ATC 
and advanced PTC patients will spend their lives undergoing and recovering from 
these conventional treatments, all for little benefit towards survival, because 
other therapy options are lacking (12).  
The goal of surgery is to remove the bulk of the tumor, and any disease 
that may be extending beyond the thyroid gland, typically through a total 
thyroidectomy, and if necessary, central and lateral neck dissection. Post-





normal thyroid tissue, adjuvant treatment for micrometastases, or for the 
treatment of residual or metastatic disease (2). Differentiated follicular thyroid 
cells uptake I-131 which induces cell death by emission of radiation, killing not 
only the cells that internalize I-131, but also any surrounding cells. Many 
dedifferentiated thyroid cancers, such as advanced PTC and ATC, will not 
respond to radioactive iodine due to the loss of the sodium-iodide-symporter, NIS 
(SLC5A5), which is required for iodine uptake (16). As a final part of conventional 
therapy, thyroid hormone suppression is recommended to not only treat post-
operative hypothyroidism, but also as TSH may contribute to the growth of 
residual or metastatic thyroid cancer cells (2,9).  
Until recently, patients with advanced, radioactive iodine-refractory 
disease had limited therapy options, as tumors that lose differentiation are no 
longer able to trap radioiodine and are unresectable due to extensive invasion 
(14). These tumor types are obvious candidates for alternative therapeutic 
approaches and understanding the molecular pathogenesis has provided the 
potential for more effective treatment strategies for these patients (6). To date, 
the development of targeted therapies has primarily focused on genotype-driven 
alterations through inhibition of receptors and kinases with small molecules. 
Accordingly, much attention has been devoted to targeting the MAPK pathway 
due to the high deregulation of this signaling pathway. Unfortunately, thyroid 
cancer patients with BRAF V600E mutations had only a 38% response to the 
BRAF-inhibitor, vemurafenib, which is a considerably lower response than 





multi-targeted kinase inhibitors have entered clinical trials for patients with 
advanced or progressing metastatic thyroid cancer, and while response rates are 
higher than traditional cytotoxic chemotherapy, only a few responses have been 
observed (8).  
Recently, the food and drug administration (FDA) has approved two multi-
kinase inhibitors, sorafenib and lenvatinib, for the treatment of metastatic, 
radioiodine-refractory thyroid cancer (11). Sorafenib and lenvatinib exert anti-
tumor effects though inhibition of vascular endothelial growth factor receptors 
(VEGFR), as thyroid cancers are associated with significantly higher vasculature 
than normal tissue. While these drugs showed longer progression-free survival 
than placebos in patients (10.8 and 18.3 months compared to 5.8 and 3.6 
months), overall survival was not significantly different between the groups (17). 
To date, these drugs are two of only four FDA-approved targeted therapies for 
patients with advanced thyroid cancer (vandetanib and cabozantinib are 
approved for treatment of advanced MTC). Of note, sorafenib and lenvatinib are 
approved for the treatment of advanced thyroid cancer without specific regard for 
the underlying molecular mechanisms responsible for drug response. So, while 
treatment options have improved slightly, the clinical efficacy of FDA-approved 




Small molecule inhibitors of protein kinases have been exceptional in 





global scale, and although these responses can be dramatic and promote 
meaningful increases in progression-free and overall survival, such treatment 
options inevitably become ineffective due to drug resistance. Mechanisms of 
resistance to targeted therapies may be intrinsic, present before therapy 
initiation, or acquired, emerging only after exposure to the targeted therapy. 
Molecular mechanism of acquired drug resistance can be grouped into 3 broad 
categories that will be discussed below: modifications within the target protein, 
activation of downstream or bypass pathways, and changes in the cellular 
phenotype that renders cancer cells less dependent on the original signaling 
pathway (Figure 1.3) (18).  
Most kinase inhibitors currently in use are small molecules that directly 
inhibit the catalytic activity of the target kinase by interfering with the binding of 
ATP. The most common and prevalent mechanism of resistance to kinase 
inhibitors is point mutations within the kinase domain of the target protein, which 
decreases drug affinity (19). Resistance is conferred by substitution mutations at 
a conserved “gatekeeper residue” in the ATP binding pocket that either increases 
affinity for ATP binding or sterically inhibits drug binding (19). Additionally, 
mutations around the ATP binding pocket may occur that can impede drug 






Drug resistance may also occur through the activation of bypass 
pathways, whereby cancer cells can replace the lack of original signal by 
activating alternative signaling pathways (Figure 1.3). Activation of bypass 
pathways can be promoted through activating mutations, increased expression, 
or autocrine stimulation of proto-oncogenes as well as deletions or loss of 
Figure 1.3: General principles of acquired drug resistance. Categories of 
resistance to kinase inhibitors include target modification, bypass signaling, 
and adaptive plasticity. Target modification occurs through mutations in the 
target protein ATP-binding pocket that increases ATP affinity or decreases 
drug binding, or by mutations outside the ATP-binding pocket that induce 
conformational changes in the target protein. Bypass mechanisms activate 
alternative pathways that signal in parallel to, or through reactivation of the 
original oncogenic pathway by mechanisms that circumvent the inhibited 
target. Adaptive plasticity mediates drug resistance through increased 
epithelial-to-mesenchymal transition (EMT), increased genes related to 
”stemness”, through changes in chromatin remodeling, and through 
adaptations in the tumor microenvironment. Adapted from Lovly C.M., et al. 






function mutations of tumor suppressors. These changes have been shown to 
occur either in parallel with the original, targeted signaling pathway, or in series 
by reactivating the original signaling pathway. An example of a parallel bypass 
pathway activation in the context of RAF inhibitors in thyroid cancer cells includes 
the redirection of RAS signaling through the PI3K/AKT pathway (20).  An 
example of a bypass pathway that occurs in series is restoration of canonical 
MAPK signaling to promote proliferation via an increase in HER2/HER3 signaling 
in response to BRAF inhibition (21).   
As studies on therapy resistance continue, increasing evidence 
demonstrates that not all resistance mechanisms are driven solely by genetic 
alterations, but can also be driven by epigenetic changes, which results in 
adaptive cellular plasticity (22). Cellular plasticity is a key feature of normal 
development and cellular processes that allows cells to respond to changing 
stimuli (23). This adaptive plasticity is retained in cancer cells, and can be used 
for therapeutic escape by acquiring motile and invasive abilities through multiple 
mechanisms including, but not limited to, increased epithelial-to-mesenchymal 
(EMT) markers and “stemness” genes, increased chromatin remodeling, and 
adaptation of the tumor microenvironment (Figure 1.3) (22). More specific 
examples of these mechanisms promoting therapeutic adaptation are shown in 
figure 1.4. Phenotype switching is the least understood mechanism of resistance 
but its importance is underlined by the observation that resistance to targeted 






                       
As existing data indicates, overall responses to single-agent targeted 
therapies in thyroid cancer have been limited, and complete responses are 
unlikely to be achieved.  As such, research towards combination therapy options 
is becoming more common, as the combination of two or more drugs may 
prevent or delay the emergence of drug resistance and may be important in 
Figure 1.4: Mechanisms that contribute to therapeutic resistance through 
cellular plasticity. The emergence of the adaptive cellular phenotype has 
been demonstrated across multiple cancer cells following treatment with all 
major classes of anti-cancer drugs, including kinase inhibitors and more 
traditional chemotherapeutic drugs. The most well studied mechanism 
mediating this change is the epithelial-to-mesenchymal transition (EMT), 
where EMT markers are increased and mediators of mesenchymal-to-
epithelial transition (MET) are decreased. Other mechanisms for therapeutic 
adaptation including increased genes related to a quiescent, stem-cell-like 
phenotype, and alterations in chromatin remodeling which ultimately affects 
cellular transcription. Microenvironment adaptation occurs when cells create 
their own protective ECM-derived niche that leads to increased AKT and 
survival signals. Other mechanisms, not shown here, also exist. Adapted from 






targeting adaptive phenotype responses (9). As thyroid cancer currently lacks 
effective single-agent targeted therapies, we sought to identify novel therapeutic 
targets for the treatment of advanced thyroid cancer and to identify upfront 
combinations that will improve the clinical efficacy of such targets.  
 
Focal Adhesion Kinase 
Signaling Components and Mechanisms of Activation   
The gene for Focal Adhesion Kinase (FAK), PTK2 (protein tyrosine kinase 
2) is located on chromosome 8 (8q24.3; Entrez Gene ID: 5747). It was originally 
identified as a 125kD protein that was phosphorylated in the presence of 
oncogenic tyrosine kinase, v-src. It was later termed FAK due to its localization to 
focal adhesions (FAs) on the cell surface that mediate cell attachment. Today, 
FAK is known to be a ubiquitously expressed non-receptor tyrosine kinase that 
functions both as a kinase and scaffolding protein by providing a link between the 
extracellular environment and the interior of the cell. Activation of FAK occurs in 
response to integrin clustering or upon activation of several growth factor or 
chemokine receptors (32). As such, FAK integrates diverse extracellular signals 
to ultimately mediate cellular processes such as cell adhesion, proliferation, 
survival, apoptosis, migration, and invasion. 
 The amino acid sequence of FAK is evolutionarily conserved among 
species; FAK homologs have been identified in human, mouse, chicken, and 
frog, with approximately 90% sequence homology (33). The structure of FAK is 
composed of four well-defined domains: 1) an N-terminal domain, 2) a central 





and 4) several proline-rich regions (Figure 1.5). Given this wide variety of protein 
domains, FAK is known to function as both a kinase and a scaffolding protein.  
Within the N-terminus, FAK contains a 4.1 exrin, radixin, moesin (FERM) 
domain which is conserved among many proteins including talins, JAKs, and 
many phosphotyrosine phosphatases (PTPs) (34). The FERM domain acts a 
negative regulator of FAK by interacting directly with the kinase domain of the 
protein to repress its catalytic activity. Experimental studies have demonstrated 
that deletion of the FERM domain promotes an increase in FAK activity (35). For 
FAK activation, the FERM domain interacts with the β-subunits of integrins, 
growth factor receptors including platelet-derived growth factor receptor 
(PDGFR), epithelial growth factor receptor (EGFR), c-MET, and RET, as well as 
chemokine receptors (Figure 1.5) (36–38). These interactions are thought to 
release the auto-inhibitory conformation of the FERM domain, resulting in FAK 
activation to facilitate outside-in signaling cascades (39). In addition, analysis of 
the FERM domain revealed nuclear export signals (NES) and a nuclear 
localization signal (NLS), which mediates shuttling of the protein in and out of the 
nucleus. Nuclear FAK, through its FERM domain, directly interacts with p53 and 
Mdm-2, to mediate ubiquitination and ultimately promote cell survival (40).  The 
FERM domain of FAK has also been shown to directly bind the transcription 
factor GATA4 to regulate anti-inflammatory signaling through vascular cell 
adhesion molecule-1 (VCAM-1) expression (41). More recently, nuclear localized 
FAK was shown to promote the transcription of chemokines through interactions 





cells, ultimately mediating an immunosuppressive microenvironment and tumor 
evasion. FAK kinase activity in the nucleus was required, and demonstrates the 
potential for small-molecule inhibitors of FAK kinase activity (42).  
As its name implies, FAK includes a central tyrosine kinase domain that 
contains catalytic activity and is necessary for mediating a variety of downstream 
signaling. Within this domain lies the autophosphorylation site for FAK, tyrosine 
(Y) 397 (Y397). Upon activation via association with integrins or growth factor 
receptors, the auto-inhibitory FERM domain is released and FAK 
autophosphorylates, through its intrinsic catalytic abilities, at Y397. It has been 
demonstrated that Y397FAK is not only a site for FAK autophosphorylation, but 
that phosphorylation can happen in trans – where activated growth factor 
receptors can directly phosphorylate this site (38).  Phosphorylation of FAK at 
Y397 creates a high-affinity binding site for SH2-containg proteins such as Src, 
phospholipase C (PLC), PI3K, and growth-factor-receptor-bound protein-7 
(GRB7) (Figure 1.5) (43). Src binding results in the release of an auto-inhibitory 
conformation of the Src protein, which allows Src to further phosphorylate key 
tyrosine residues on FAK. The formation of the complex with Src is the most 
critical event in FAK signaling. Src phosphorylates residues within the catalytic 
domain, Y576 and Y577, and phosphorylation at these residues tightly controls 
FAK kinase activity (44). The mutually activated FAK/Src complex then initiates a 
cascade of phosphorylation events that ultimately lead to different cellular 






Figure 1.5: FAK protein structure, phosphorylation sites, and binding 
partners. FAK contains a FERM (4.1, ezrin, radixin and moesin homology) 
domain, a kinase domain and a focal adhesion targeting (FAT) domain. The 
FERM domain mediates interactions of FAK with PDGFR, EGFR, c-MET and 
RET for FAK activation and signaling. FAK FERM domain interactions with 
ARP2/3 and N-WASP controls actin dynamics. FAK binds p53 and Mdm-2 
through its FERM domain to mediate p53 expression. FAK FERM domain also 
binds the transcription factor GATA-4 to control VCAM-1 expression. The FAT 
domain recruits FAK to focal contacts by associating with integrin-associated 
proteins such as talin and paxillin. It also links FAK to the activation of Rho 
GTPases by binding to GEFs such as p190RhoGEF and GRAF. FAK contains 3 
proline rich regions, which bind SH3 domain-containing proteins such as 
p130Cas, GRAF, ASAP1, and endophilin A2. FAK is phosphorylated (P) on 
several tyrosine residues, including 397, 576, 577, 861, and 925. 
Phosphorylation at Y397 creates a high affinity SH2 binding site for Src, the 
catalytic subunit of PI3K, PLC, and GRB7. Phosphorylation of Y576 and 577 
within the kinase domain is required for maximal FAK catalytic activity. Binding 
of FIP200 to the kinase region inhibits FAK kinase activity. FAK auto-inhibition is 
controlled by binding between sites in the FERM and kinase domains, marked 
by yellow boxes. FAK phosphorylation at Y861 is required for p130Cas binding 
and phosphorylation at Y925 creates a binding site for the GRB2 adaptor 
molecule for signaling through the MAPK pathway. FAK also contains one 
nuclear localization signal, located in the FERM domain (denoted by a blue box), 
and two nuclear export signals, one in the FERM domain and one in the kinase 
domain (denoted by the red boxes). Adapted from Sulzmaier, F.J., et al. Nature 






The C-terminal domain contains a focal adhesion targeting (FAT) 
sequence, which is necessary for localizing FAK to FAs. This is thought to occur 
through direct contact with FAT domains of other cytoskeleton-interacting 
proteins including paxillin and talin (Figure 1.5) (45,46). FAK dimerization through 
binding of FERM and kinase domains, requires stabilizing interactions between 
the FAT and FERM domains, and plays an important role in FAK activation and 
nuclear localization. FAK dimerization occurs only at FAs and paxillin mediates 
this interaction by recruiting FAK and reinforcing the FAT:FERM interface (47). 
The FAT domain also associates with several Rho GTPases, including 
p190RhoGEF and GRAF (48). Several Src-specific phosphorylation sites lie 
within the FAT domain, including Y861 and Y925. Phosphorylation of Y861 
regulates the interaction of the adaptor protein p130Cas (BCAR1) to FAK proline-
rich regions and promotes association of FAK with αvβ5 integrins after vascular 
endothelial growth factor (VEGF) stimulation (49). Phosphorylation of Y925 
provides a binding site for the Grb2 adaptor protein to facilitate a Ras/MAPK 
signaling cascade (Figure 1.5) (50).    
In addition to these three major domains, FAK contains three proline-rich 
(PR) regions that mediate interactions with SH3-domain containing proteins, 
including p130Cas, as discussed above, which exerts a motility signal through 
activation of Rac (51). Other proteins that bind to PR regions on FAK include 
GRAF and ASAP1, which have been implicated in FA assembly and cytoskeleton 





As FAK regulates a variety of downstream signaling pathways, precise 
control of FAK is required to ensure proper spatial and temporal regulation of 
cellular processes. As such, there are many mechanisms regulating FAK 
activation. First, as discussed above, intra-molecular interactions between the 
FERM domain and the kinase domain of FAK promotes an auto-inhibitory state. 
Only upon interaction with the cytoplasmic tails of integrins or growth factor 
receptors is the auto-inhibitory conformation disrupted, resulting in increased 
FAK kinase activity (34). Also discussed above, FAK dimerization is a key step in 
activation, as it promotes autophosphorylation at Y397 (47). In addition, 
phosphorylation is an important mechanism regulating FAK activity. PTPs, 
including PTP-PEST, PTPα and SHP2, as well as PTEN, can act directly or 
indirectly to dephosphorylate FAK and reduce its catalytic activity (53–57) In 
addition, cellular stimuli, such as elevated intracellular pH and changes in the 
extracellular matrix composition and rigidity, can influence FAK activity (58,59). 
Furthermore, FAK can also be regulated by association with specific protein 
binding partners, such as FIP200 and ephrin type-A, which function as inhibitors 
of FAK through direct binding to the kinase domain resulting in inhibition of FAK 
catalytic ability (34,60).  
 
Role in Normal and Pro-tumorigenic Processes  
FAK is ubiquitously expressed across all tissues and its importance in 
development and normal cellular processes is emphasized by studies using 
genetically engineered mice. These studies are summarized in table 1.1. Briefly, 





cardiovascular development, suggesting that FAK is essential in endothelial cells 
for angiogenesis and vasculogenesis (61). Homologous knock-in mutations of a 
kinase-dead FAK demonstrated embryonic lethality at E9.5, again due to defects 
in vasculogenesis (62). Deletion of exon 15 of FAK, which contains the Y397 site, 
showed normal development of embryos to day E12.5, but lethality at E13.5-14.5 
due to delayed artery formation, vascular remodeling defects, and multiple organ 
developmental abnormalities (63).  
 
 
These studies demonstrate that FAK is an essential protein that has various 
kinase-dependent and –independent (scaffolding/adaptor) mediated biological 
effects. FAK-mediated pathways involved in specific cellular processes relevant 
in tumor malignancy and progression are shown in figure 1.6 and will be 
described below.  
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Figure 1.6: FAK signaling targets and pathways that regulate specific 
processes critical for tumorigenesis and cancer progression. FAK drives 
cancer growth and metastasis through kinase-dependent (red circles) or kinase-
independent (yellow diamonds) functions. FAK promotes cell survival through 
kinase-dependent effects on PI3K/AKT pathway, IAPs, NFk-B, JNK, paxillin, 
and p130Cas, and mediates p53 degradation in the nucleus through its 
scaffolding functions. FAK regulates cell proliferation by controlling G1 to S 
phase transition through both kinase and scaffolding functions.  EMT is 
mediated by E-cadherin internalization and MMP surface expression, which are 
FAK kinase-dependent and –independent effects, respectively. Active FAK 
increases cell motility through effects on RhoGEFs and GTPases, and p130Cas 
and paxillin signaling. FAK scaffolding functions mediate p130Cas signaling and 
binds ARP2/3 and N-WASP directly, which drives cytoskeleton remodeling, and 
focal adhesion formation and turnover. FAK kinase-dependent and –
independent functions regulate the expression and cell-surface presentation of 
matrix metalloproteinases (MMPs), therefore enhancing cell invasion and tumor 







 Cell survival. FAK plays an integral role in tumorigenesis by promoting 
sustained proliferative and survival signals. Disruption of integrin-mediated cell-
ECM adhesion induces anoikis, a form of apoptosis resulting from detachment 
from the basement membrane. However, enhanced FAK signaling promotes 
anoikis-resistance in cancer cells through activation of the PI3K/AKT survival 
pathway (64–66). Cross talk between the FAK/Src signaling complex and many 
of its downstream signaling components, including JNK and p130Cas, p53, and 
paxillin, can contribute to anoikis resistance (67–69). A protective role of FAK in 
apoptosis also includes the promotion of the anti-apoptotic effects of NF-kB and 
inhibitory apoptosis proteins (IAPs) (Figure 1.6) (64,70). Inhibition of FAK has 
also been shown to enhance cytotoxicity of chemotherapeutic drugs, potentially 
by inhibiting the FAK-induced survival pathway activation and rendering cells 
more sensitive to chemotherapeutic agents (71–74). 
Cell proliferation. Additional studies have revealed that FAK mediates 
cell proliferation via regulation of the cell cycle, by controlling the G1 to S phase 
transition. Targeting the adaptor molecule Grb2 to FAK enhances cell cycle 
progression through activation of the MAPK pathway (75).  Enhanced FAK 
signaling increases expression of cell cycle regulators such as cyclin D3 and D1, 
and decreases expression of specific cyclin-dependent kinase (CDK) inhibitors, 
such as p21 and p27, all of which promote cell cycle progression (76–79). In 
addition, recruitment and subsequent phosphorylation of p130Cas by the 
FAK/Src complex promotes activation of JNK and c-Jun, which regulates 





cycle progression through its effects in the nucleus, as discussed above, by 
mediating the ubiquitination and degradation of p53 (Figure 1.6) (40).  
 Cell migration. FAK has long been a known regulator of cell migration 
and invasion and therefore a probable moderator of metastasis. Cell motility 
requires establishment of cellular polarization, formation of cellular protrusions 
that attach to the substratum at the leading edge, and the regulated contraction 
and disassembly of FAs at the trailing edge, all of which generates traction and 
forward movement (81).  
Cellular polarization requires the coordinated actions of the Rho family of 
GTPases, and their downstream effectors, as these molecular switches are 
responsible for cell contraction and “direction-sensing” or polarization, which is 
necessary for cells to move in a forward motion. These GTPases, enzymes 
responsible for the hydrolysis of GTP, are tightly controlled by FAK function as 
phosphorylated FAK recruits GTPases through its scaffolding functions thereby 
promoting increased GTPase activity (82). FAK regulates the activity of GTPases 
such as p120RasGAP, p190RhoGAP, RhoA, Rac, and Cdc42 (Figure 1.6) 
(48,81,83).  In addition to polarization, GAPs and GEFs signals coordinate cell 
migration as they mediate “push” and “pull” signals, respectively, to promote cell 
contraction (82).  
The generation and maintenance of cellular protrusions, through 
reorganization of the actin-cytoskeleton, is an important step in mediating 
efficient cell movement. The best characterized downstream effectors of the 





mentioned previously, p130Cas binds to Src-induced phosphorylation of Y861 on 
FAK, which leads to enhanced phosphorylation of p130Cas at multiple sites (84). 
This facilitates binding of the adaptor protein Crk, that in turn recruits ELMO and 
Dock180 to provide GEF activity towards Rac, and ultimately promotes 
lamellipodia formation and the stabilization of FA complexes (85). Likewise, 
phosphorylation of paxillin by the FAK/Src complex promotes Crk binding and 
subsequent downstream signaling (86). In addition, FAK can bind and 
phosphorylate N-WASP, which functions to recruit and activate Arp2/3, thereby 
mediating the formation of branched actin networks and leading to the assembly 
of lamellipodia (Figure 1.6) (87).  
The regulated assembly and disassembly of FAs is necessary for 
controlled, directional movement. Studies show that cells deficient in FAK exhibit 
larger FAs at the cell periphery and have a poor rate of migration (61). 
Overexpression of FAK stimulates cell migration, and the kinase activity of FAK 
plays an important role in this process, as FAK phosphorylates -actinin and 
modulates its ability to crosslink actin stress fibers, impacting FA maturation and 
turnover (37,88,89).  FAK-mediated ERK localization to adhesions promotes 
phosphorylation of myosin-light-chain kinase (MLCK) and increases contractility, 
which destabilizes then disassembles FAs (90).  Additionally, the FAK/Src 
complex controls FA dynamics through the phosphorylation of paxillin (91). 
Further, FAs are controlled by FAK functions in a kinase-independent manner by 
acting as an adaptor molecule for the FAK-Src-ERK2-Calpain-2 complex after 





stimulation. This regulates the release of points of attachment between the cell 
and the surrounding extracellular matrix (ECM) (52,90). Caspase-8 also forms a 
complex with FAK and calpain-2 to destabilize FAs, which promotes efficient cell 
motility (Figure 1.6) (92).  
Cell invasion. FAK has a proposed function in cell invasion, a process 
that requires the active proteolytic degradation of the surrounding extracellular 
matrix and migration into the surrounding tissue (93). FAK overexpression in v-
src transformed fibroblasts was associated with the co-localization of FAK/Src 
complex together with 1 integrins at invadapodia protrusions and correlated with 
increased cell invasion through Matrigel (94). Accordingly, expression of the 
dominant-negative FAK construct in fibroblasts inhibited invasion through 
Matrigel, and suppressed experimental lung metastases in nude mice, all without 
altering migration. These effects were attributed to the decreased expression and 
secretion of matrix-metalloproteinase (MMP) -2 (95). Further studies also support 
a role for FAK signaling in the expression of other MMPs, such as MMP-9, 
potentially through the formation of a FAK-Src-p130Cas-Dock180 signaling 
complex and subsequent Rac, JNK and ERK activation (51,95). Consistent with 
the scaffolding function of FAK mediating MMP expression, endophilin A2 
phosphorylation by Src is increased upon binding to FAK, which has been shown 
to reduce endocytosis of MT1-MMP thereby increasing its expression on the cell 
surface (Figure 1.6) (96). Together, these studies support a role for FAK in cell 





 Epithelial-to-mesenchymal transition. EMT is thought to be an 
important step in cancer progression. As its name suggests, EMT has been 
characterized by the acquisition of a mesenchymal and loss of an epithelial 
phenotype, increase migratory and invasive potential, increased production in 
ECM components, enhanced resistance to apoptosis, and as discussed above, a 
mechanism for therapeutic escape (97,98). Both FAK and Src play important 
roles in the process of EMT. For example, FAK/Src complex signaling is required 
for transforming growth factor beta (TGF ) induced EMT by regulating 
transcription of mesenchymal/invasive proteins, such as MMP-9 and fibronectin, 
and downregulating epithelial proteins such as membrane-bound E-cadherin 
(99). The FAK/Src complex also promotes the dissolution of E-cadherin-
containing intracellular junctions, leading to increased cellular migration/invasion 
(100,101). EMT can be induced by the transmembrane serine protease, 
TMPRSS4, by activating FAK/Src signaling (43). In addition, inhibition of FAK/Src 
has been shown to stabilize cell-cell contacts to impair collective cell movement 
(Figure 1.6) (102).  Overall, these studies demonstrate a key role for FAK, in 
association with Src, in regulating EMT.  
 
FAK as a Potential Therapeutic Target  
FAK activity is vital during development and it controls diverse cellular 
processes, including survival, proliferation, migration, and invasion. As such, it is 
not surprising that FAK also regulates key biological properties associated with 
normal cellular function and disease, such as cancer initiation and progression, 





FAK expression has been extensively studied in tumor tissues and the 
results are extremely conflicting. FAK expression and its correlation with 
prognostic factors in different cancer types is listed in table 1.2. FAK has been 
demonstrated to be upregulated in a variety of human epithelial cancers, with 
expression being closely correlated to the invasive potential. High FAK 
expression in tumor samples has been found in hepatocellular carcinomas (103), 
invasive breast carcinomas (104,105), intestinal-type gastric carcinoma (106), 
endometrial cancer (107), and acute myelogenous leukemia (108). In each case, 
high FAK expression associated with a worse outcome. FAK upregulation was 
found in most studies to be due to amplification of the FAK gene or increased 
messenger RNA (mRNA) transcripts, which lead to increased protein expression. 
Analysis of the FAK gene promoter identified p53 and NFB as direct repressors, 
and activators of FAK expression, respectively (109,110).  
On the other hand, conflicting data shows no prognostic value of FAK 
expression in node-negative breast cancer, colon carcinomas, or resectable 
pancreatic cancer (111–113). To further these discrepancies, other studies have 
shown that high FAK expression relates to a better outcome for patients, as 
demonstrated in diffuse-type gastric carcinomas and cervical cancers (106,114). 
In thyroid cancer, FAK staining was observed in the cytoplasm of the follicular 
cells of PTC, FTC, MTC, and ATC samples, while no FAK staining was observed 















































development of thyroid cancer (115). In addition, FAK mRNA expression 
in thyroid cancer samples correlated with more invasive and aggressive subtypes 
(116). The conflict of multiple studies strongly implies that the prognostic ability of 
FAK may largely be cell and context specific, and may rely on FAK activity and 
localization, not just expression.  
Given the expression of FAK in many human cancers, studies have 
employed the use of genetic murine models in an attempt to better understand 
the role that FAK plays in tumorigenesis. These are summarized in table 1.1.  In 
a chemically-induced model of skin carcinogenesis, deletion of FAK inhibits the 
conversion of papillomas to squamous-cell carcinomas, suggesting a role for 
FAK in tumor initiation and progression (Table 1.1) (117).  The most in-depth 
studies come from breast cancer research,  where the specific role of FAK was 
addressed using mouse mammary tumor virus polyoma middle-T (MMTV-PyVT) 
transgenic model of human breast cancer, which recapitulates the multi-step 
progression of human breast cancer by advancing from the beginning stages of a 
hyperplastic phenotype, all the way to late carcinoma formation with pulmonary 
metastasis (118). In these studies, tissue-specific ablation of FAK, through Cre-
recombination, significantly delayed tumor formation but did not inhibit tumor 
formation entirely (119–122). However, analysis of the neoplastic lesions in the 
FAKflox/flox mice confirmed that the tumors had originated from cells that had 
escaped Cre-mediated recombination, suggesting a stringent role for FAK in 
mammary tumor initiation (119). Interestingly, FAK-null epithelial cells were also 





such, FAKflox/flox mice presented with largely benign, non-invasive tumor 
phenotypes compared to tumors in FAK-positive mice that progressed to invasive 
carcinomas, and had a 50-fold increase in pulmonary metastases (Table 1.1) 
(120). The ability of FAK to specifically support mammary oncogenesis was 
shown to depend on the integrity of the proline region containing Pro712/713, 
which mediates the interaction with p130Cas, further suggesting a role for FAK 
scaffold functions in pro-tumorigenic processes. In addition however, rescue 
studies using a FAK kinase dead construct demonstrated that FAK catalytic 
ability was also important in tumorigenesis (119). Together, these studies 
suggest that FAK mediates tumor initiation, progression, and conversion into 
more aggressive, and invasive cancer phenotypes. 
 
Potential Applications for FAK Inhibitors 
As FAK activity plays an important role in tumor survival, invasion, and 
metastasis, more interest has been placed on targeting FAK in cancer. The initial 
attempts to inhibit FAK in cancer cells included the addition of antisense FAK 
oligonucleotides, and expression of adenoviral dominant-negative FAK 
constructs, or FAK short inhibitor RNA (siRNA).  These methods effectively 
downregulated FAK protein, decreased cell viability, and increased cell 
apoptosis, providing proof-of-principle for the development of more clinical 
relevant pharmacological approaches (123–125). As such, several orally 
available small molecule inhibitors of FAK have been developed and some have 
entered clinical trials (126). FAK inhibitors can be divided into 3 main groups: 





that target other sites on FAK yet still blocks the kinase activity, and inhibitors 
that target the scaffolding functions of FAK by blocking protein-protein 
interactions (127). FAK inhibitors with pre-clinical and clinical data are listed in 
table 1.3. The following discussion will focus on the first generation FAK inhibitor, 
PF-573,228, ATP-competitive inhibitors that are in clinical trials, and molecules 
developed to target the scaffolding functions of FAK.  
 
 
The first generation FAK inhibitor PF-573,228 (Pfizer) is an ATP-
competitive inhibitor of FAK that provided functional insight and structural 
knowledge for the daughter compounds, including PF-562,271 and PF-04554878 
(Pfizer), which were acquired by Verastem and are now known as VS-6062 and 
defactinib (VS-6063), respectively, of which defactinib is currently being 






evaluated in clinical trials.  PF-573,228 inhibits FAK in vitro with an IC50 value of 
4nM and functions by inhibit FA turnover, thereby reducing cell migration. 
However, early studies demonstrated that PF-573,228 had no effect on cancer 
cell growth or survival due to compensatory upregulation of the FAK homologue, 
PYK2 (126). As such, the second generation FAK inhibitors PF-562,271 (VS-
6062) and PF-04554878 were developed as orally available inhibitors of both 
FAK and PYK2 enzymatic activity, with in vitro IC50 values of 1.5 and 14nM, 
respectively (128). Numerous studies have demonstrated the effects of PF-
562,271 on cell migration, invasion, and metastasis (102,129,130). Like the 
mother compound PF-573,228, limited efficacy on biological processes such as 
cell proliferation and apoptosis was observed in cells grown in a monolayer 
(128,129). However, PF-562,271 was shown to inhibit growth and induce 
apoptosis in assays promoting anchorage-independent growth and in a variety of 
cancer types (128,129,131). Due to the large amount of pre-clinical data, PF-
562,271 was the first FAK-directed agent to enter clinical trials.  
 Defactinib, a derivative of PF-562,271, has been the most successful FAK 
inhibitor in clinical trials. Phase II clinical trials have recently been completed in 
patients with KRAS-mutant non-small cell lung cancer (NCT01951690) and 
malignant pleural mesothelioma (NCT02004028), but study results have not yet 
been released. Other phase II clinical trials with defactinib are currently recruiting 
patients with advanced solid malignancies, lymphomas, and multiple myeloma. In 
addition, several phase I trials determining the pharmacokinetic and 





completed in a variety of patients, including those with solid tumors, and shows 
reduced pY397FAK levels by ~80% compared to baseline at concentrations 
below the maximum tolerated dose (132).  
An approach that is still in pre-clinical stages is targeting the Y397 site on 
FAK via allosteric binding. This technique results in increased selective targeting, 
as it does not bind to the ATP-binding pocket that is highly conserved between 
tyrosine kinases such as Pyk2 and Src (133).  Compounds developed by a group 
at the Roswell Park Cancer Institute, such as Y15, inhibit Y397 
autophosphorylation and promote cell detachment, inhibit cell adhesion, and 
decreases cell survival through induction of apoptosis (74,133,134). Of 
importance, the functional mechanism of these compounds will inhibit not only 
FAK kinase activity, but also FAK protein-protein interactions at Y397, including 
Src and PI3K (135).   
The most recent and least experimentally validated method for FAK 
inhibition is targeting FAK scaffolding/adaptor functions. Small molecules that 
inhibit the kinase activity of FAK are not effective against FAK scaffold/adaptor-
mediated signaling. However, as more evidence demonstrates a kinase-
independent role for FAK in mediating pro-tumorigenic processes, therapeutic 
approaches to block the protein-protein interactions (PPIs) between FAK and its 
many binding partners are becoming more desirable. A small number of 
compounds have been developed by CureFAKtor Pharmaceuticals that are 
currently undergoing pre-clinical tests. For example, compound R2 was 





regulate expression of p53 (136). Other FAK PPIs that have successfully been 
targeted are VEGFR3 via the C4 compound, cMET/IGFR1, and p53, all of which 
have been shown to effectively reduce cell viability and tumor growth 
(134,135,137–139). Therefore, pharmacologically inhibiting PPIs is feasible and 
targeting the scaffolding/adaptor functions of FAK can have detrimental effects 
on tumor growth and survival.  
Based on the evidence presented, the mechanisms by which FAK 
mediates tumorigenic processes is exceedingly complex and likely context 
dependent. Increased FAK expression and activity has been identified in thyroid 
cancer however the role that FAK plays in this setting is relatively unknown. As 
such, this thesis aims to dissect the dual roles of FAK (kinase versus scaffold) in 
pro-tumorigenic process of thyroid cancer and to identify how best to target FAK 
to provide the greatest clinical benefit.  
 
Thesis Direction and Summary 
Recently, much effort has been put forth to understanding the molecular 
mechanisms involved in the pathogenesis and progression of advanced thyroid 
cancer. However, little progress has been made in the development and 
identification of effective therapeutic interventions. Single-agent therapies 
targeting known oncogenic drivers and pathways have had limited efficacy thus 
far, and complete response are unlikely to be achieved. This problem is two-fold: 
1) novel therapeutic targets for the treatment of advanced thyroid cancer are 
lacking and need to be identified; and 2) upfront combination therapies to 





developed, as combinations are expected to prevent drug resistance. As such, in 
Chapter III, I will provide evidence demonstrating that FAK is a novel target in 
advanced thyroid cancer, and that FAK scaffolding functions are fundamental in 
the regulation pro-tumorigenic processes. This work further demonstrates that 
the kinase activity of FAK is dispensable, and that targeting the scaffolding 
function(s) of FAK in thyroid cancer would be of the most benefit to patients with 
advanced thyroid cancer. In Chapter IV, I will demonstrate that chronic treatment 
with a Src inhibitor in BRAF-mutant thyroid cancer promotes a key switch in FAK 
dependency from scaffolding/adaptor function to kinase activity, which drives 
resistance to Src-directed therapies through adaptive plasticity and increased 
reliance on a p130Cas /c-JUN signaling module. This work also identifies a 
rational, upfront combination therapy, which targets the kinase activity of both 
FAK and Src to increase therapeutic efficacy. This may provide the advantage of 
inhibiting both the proliferative and invasive populations, which can mediate drug 
resistance and cancer recurrence. Taken together, the work included in this 
thesis provides evidence of the complexity of FAK signaling and provides insight 
into therapeutic strategies that may improve the survival of patients with 











MATERIALS AND METHODS 
 
Reagents 
PF-562,271 and PF-573,228 used in vitro were either provided by Pfizer 
or purchased from Sigma. The PF-562,271 used in vivo was either provided by 
Pfizer or purchased from SelleckChem. Dasatinib was obtained from LC labs. 
MMP inhibitors GM6001 and SB-3CT were purchased from MedChem Express.  
The TGFβ receptor type I inhibitor, SB431542, was from SelleckChem. The 
neutralizing antibody against human IL-1β was obtained from R&D bio-techne. P-
aminophenylmurcuric acetate (APMA), for MMP activation was from Sigma.  All 
drugs used in vitro were dissolved in dimethyl sulfoxoide (DMSO) (Sigma).  
 
Cell Culture 
Human thyroid cancer cell lines BCPAP, 8505C, and Cal62 were provided 
by M. Santoro (Medical School, University of Naples Federico II, Naples, Italy). 
SW1736 and C643 cells were obtained from Dr. K. Ain (University of Kentucky, 
Lexington, KY) with permission from N. E. Heldin (University Hospital, Uppsala, 
Sweden). TPC1 cells were provided by S. Jhiang (Ohio State University, 
Columbus, OH).  TJH11T and THJ16T cells were obtained from J. A. Copland 
(Mayo Clinic Comprehensive Cancer Center, Jacksonville, FL).  Cells resistant to 
dasatinib (BMS-354825) were generated as previously described (140). Briefly, 
cells were cultured in gradually increasing concentrations of dasatinib or in 





until cells were maintained in 2µM dasatinib. Resistance to dasatinib was 
measured via sulforhodamine B (SRB) assays as previously described (141). 
Control and dasatinib-resistant cells were treated with 30nM and 2M dasatinib, 
respectively, unless otherwise indicated. Prior to use in experiments, all cell lines 
were validated using short tandem repeat profiling using the Applied Biosystems 
Identifiler kit (#4322288) in the Barbara Davis Center BioResources Core Facility, 
Molecular Biology Unit, at the University of Colorado, or as previously described 
(142).  Cells were also tested for Mycoplasma contamination using Lonza 
Mycoalert system according to the manufacturer’s directions prior to use. Cells 
were grown in RPMI (Invitrogen) containing 5% FBS (Hyclone) and maintained at 
37°C in 5% CO 2. Cell lines were passaged no more than 30 times after thawing.  
 
Cell Morphology and Aspect Ratio Analysis 
Control and dasatinib-resistant cell lines (BCPAP, SW1736, Cal62, and 
C643) were plated in 6-well plates and allowed to adhere for 48 hours. Brightfield 
images were collected at 10X magnification and used to visualize overall cell 
shape. For each cell line, 200 cells were quantified by ImageJ (NIH) and the 
aspect ratio was calculated as a function of length versus width.  
 
Cellular Doubling Time 
To calculate doubling time, BCPAP (3.0 x104), SW1736 (2.5 x104), Cal62 
(3.0 x103), and C643 (2.0 x104) control and dasatinib-resistant cells were plated 
on Day 1 and then harvested and counted on days 3, 5, and 7. Doubling time 





 �� = ʈ × log � � −log  where t = time, n1= initial cell concentration, and n2= final 
cell concentration.  
 
Generation of Conditioned Media 
Conditioned media was generated as previously described (143). Briefly, 
BCPAP (4 x 106), SW1736 (3 x 106), Cal62 (2 x 106), and C643 (3 x 106) 
dasatinib-sensitive (control) and –resistant cells were plated in 15-cm dishes with 
regular growth media. After 24 hours, the media was replaced with media 
containing 1% FBS. After 72 hours, (~80% cell confluency) the media was 
collected, centrifuged @ 1000 rpm for 5 minutes, filtered through 0.45um pore 
size, aliquoted, and stored at -80° until use.  
 
Viral Transfections and Generation of Stable Cell Lines 
Short-hairpin RNA (shRNA) targeting human FAK (Sigma mission 
TRCN0000121318 and TRCN0000121319), a scramble control (Sigma mission 
pLKO.1-puro, SHC002) and shRNA targeting human P130Cas (Sigma mission 
TRCN0000115984), and a scramble control (Sigma mission pLKO.1-puro 
SHC016) were packaged for lentiviral delivery via HEK293T cells using Effectene 
Transfection reagent (Qiagen), according to manufacturer instructions. Briefly, 
HEK29T cells were seeded in 10 cm dishes to be ~90% confluent the next day. 
Expression vector (5µg), and packaging vectors V1 (1.5µg) and V2 (1.5µg) were 
mixed with EC buffer (450µL final volume). Following the addition of enhancer 
reagent (40uL per reaction) and Effectene reagent (75uL per reaction), the 





The transfection mixture was then combined with media (1mL per reaction) and 
added to HEK293T cells, which contains 8mL media. Media containing viral 
particles was collected after 48 and 72 hours, centrifuged, filtered through 
0.45um pore, aliquoted, and stored at -80°.  
BCPAP, 8505C, and Cal62 as well as the BCPAP and Cal62 control and 
dasatinib-resistant cells were virally transfected by plating 1x105 cells in wells of 
6-well plates and adding 1mL virus to 1mL media in the presence of 8µg/ml 
polybrene. The media was changed after 24 hours, and 48 hours post-
transfection, antibiotic selection was added. Selection was achieved with 
puromycin. Transductions of shRNA targeting FAK and the scramble control 
were performed for each individual experiment. Transfection of BCPAP control 
and dasatinib-resistant cells with shRNA targeting p130Cas and the scramble 
control SHC016 was performed once and stably selected before experiments 
were performed.  
SW1736 dasatinib-resistant cells were transduced with pBabe-hygro and 
pBabe-c-Src-Dasatinib-Resistant-T3381 (Addgene plasmid 26980) retrovirus and 
selected with hygromycin, as previously described (141).  
 
Cellular Viability Assays 
For pharmacological studies, BCPAP (1x104) or 8505C (5x103) cells were 
treated with 1 M PF-573,228 (Pfizer) or DMSO every 3 days for 6 days. For 
genetic studies, shFAK- or scramble control- expressing cells were plated and 
the media was changed every 3 days for 6 days. Cells were then harvested with 





counted using a Beckman Coulter Vi-CELL cell counter with trypan blue 
exclusion as previously described (142).  
 
Sulforhodamine B (SRB) Assays 
For SRB assays, cells were plated as previously described (141) and 
treated with the indicated concentrations of dasatinib, PF-562,271, or PF-
573,228. Growth was calculated as a percent of DMSO-treated control. IC50 
values were calculated using PRISM software and fold-change was calculated. 
Synergy was calculated using Bliss independence model, which is derived from 
the complete additivity of probability theory and takes into account limited 
inhibition responses from single-agent drug 
 
Soft Agar Assay 
Cells (1x104) were suspended in 0.35% agar with complete media and 
plated on a base layer of 0.6% agar (Difco Agar Noble, BD Biosciences). For 
pharmacological studies, cells were treated with vehicle (DMSO) or 1 M PF-
573,228 after 24 hours. Media containing vehicle or drug was replenished every 
3 days for a total of 20 days. Colonies were stained with nitroblue tetrazolium 
chloride (Amresco; 5 mg/ml), and incubated overnight at 37°C to develop the 
stain. Colonies were counted using ImageJ software.   
 
Adhesion Assays 
BCPAP or 8505C cells plated onto 15-cm dishes (~70% confluent) were 
serum starved in RPMI with 0.1% FBS and treated with 1 μM PF-573,228 or 





with PBS, and resuspended in Assay Buffer (Millipore) supplemented with 1 μM 
PF-573,228 or DMSO. BCPAP (1.5 x 105 cells/well) or 8505C (7.5 x 104 
cells/well) cell suspensions (100 μL) were added in duplicate to each well of the 
ECM Array Plate (Millipore) and incubated for 2 hours at 37°C in 5% CO 2. Wells 
were aspirated, washed, and stained for adherent cells. Cell bound stain was 
solubilized and absorbance was measured at 570 nm. 
 
Western Blotting 
Cells treated with the indicated doses of dasatinib, PF-562,271, PF-
573,228 or DMSO were harvested in 3-((3-cholamidopropyl) dimethylammonio)-
1-propanesulfonate (CHAPS) lysis buffer (10mM CHAPS, 50mM Tris (pH8.0), 
150mM NaCl and 2mM EDTA) with 1x phosphatase and protease inhibitor 
cocktail (Roche). Protein concentration was quantified using BioRad DC Protein 
Assay, according to the manufacturer’s instructions. Protein lysates resolved on 
SDS-PAGE gels were transferred to Immobilon-FL membranes (Millipore) and 
incubated at 4°C overnight with the following antibodies:  Total FAK, Total 
p130Cas (BD Bioscience); pY397FAK (Abcam); pY925FAK, PYK2, pY416Src, 
pY527Src Total Src, pY410p130Cas, ppERK 1/2, Total ERK 1/2, pS473AKT, 
pT308Akt, Total AKT, ppT180/Y182p38, Total p38, Total c-JUN, pS63c-JUN 
(Cell Signaling); pY861FAK, pS910FAK, pY40βPYKβ (invitrogen); α-tubulin 
(CALBIOCHEM) diluted in 1:3 Odyssey® Blocking Buffer in TBST (LICOR). Blots 
were incubated with secondary goat anti-mouse or anti-rabbit IRDye-conjugated 







Undiluted conditioned media, collected as described above, from BCPAP 
and Cal62 control and dasatinib-resistant cells was applied to a human cytokine 
antibody array (Abcam, ab1γγ997) and processed per the manufacturer’s 
instructions. Analysis was performed after the background signal was subtracted 




For FAK inhibitor studies, BCPAP (5 x 105) and 8505C cells (4 x 105) were 
starved in RPMI with 0.1% FBS and treated with PF-573,228 or DMSO at the 
indicated concentration. For the dasatinib-resistance studies, control and 
dasatinib-resistant BCPAP (7.5 x 105), SW1736 (1 x 106), Cal62 (1 x 106), and 
C643 cells (1 x 106) were starved in RPMI with 0.1% FBS and treated with 
DMSO, dasatinib, PF-562,271, combination of PF-562,271 and dasatinib, 
SB431542, or the neutralizing antibody anti-IL1β, at the indicated concentrations. 
For conditioned media experiments, cell media was changed to 1% FBS. After 24 
hours, cells were harvested and seeded in the upper chambers of Matrigel-
coated transwells (24-well, 8 M pore size; BD Biosciences) in 0.1% FBS RPMI 
with the appropriate drug/combination. RPMI with 10% FBS and the appropriate 
drug/combination was added to the lower chamber. For conditioned media 
experiments, conditioned media with or without drug as appropriate was added to 
either the upper or lower chamber, with 1% FBS with/without drug in the opposite 





3CT (6µM) was added to the upper and lower chamber. Cells were allowed to 
invade for 24 hours. Invading cells on the lower surface of the membrane were 
fixed with methanol for one minute and stained with 4’,6-diamidno-2-phenylindole 
(DAPI) (3 g/mL, Invitrogen). Nuclei were quantified in five microscope fields 
under 10X magnification using ImageJ software and a Nikon microscope. 
Proliferation assays using Vi-CELL were performed in parallel and invasion was 
normalized for changes in cellular growth.  
 
Migration Assays 
Migration assays were performed similarly to invasion assays but cells 
were plated in uncoated transwells (24-well, 8.0um pore size; Falcon) and 
allowed to migrate towards 10% FBS. Proliferation assays using Vi-CELL were 
performed in parallel and migration was normalized for any changes in cell 
growth. 
 
RNA Collection and Quantitative RT-PCR  
BCPAP (5.0 x 105) and Cal62 (3.0 x 106) cells were treated with the 
indicated concentrations of dasatinib, PF-562,271, or the combination. After 24 
hours, total RNA was isolated using the RNeasy kit (Qiagen) and reverse 
transcribed using the High Capacity c-DNA kit (Applied Biosystems). Primers 
were designed with assistance of the Prism 7900 sequence detection software 
(Primer Express, PE ABI). The following primer/probe sequences were used as 
listed in table 2.1.  Amplification reactions were carried out at the Endocrine PCR 





optical plates (ABI/Life Tech) in a 20µL mix containing 1X TaqMan Buffer A  
(500mM KCl, 100mM Tris-HCL, 100mM EDTA, 600nM passive reference dye 
ROX, pH8.3 at room temperature), 300µM each of dATP, dGTP, dCTP, and 
600µM dUTP, 5.5mM MgCl2, 900nM of both forward and reverse primers, 200nM 
probe, 1.25 U AmpliTaq Gold DNA Polymerase and the template cDNA. Thermal 
cycling conditions were as follows: Hold for 2 minutes at 50°C followed by 
activation of TaqGold at 95°C for 10 minutes. Subsequently 40 cycles of 
amplification were performed at 95°C for 15 seconds and 60°C for 1 minute. After 
amplification, real-time data acquisition and analysis were performed. The 
detection threshold was set above the mean baseline florescence, determined for 
the first 15 cycles after being normalized to background signal. A 10-fold serial 
dilution of cDNA from control RNA was used to generate the standard curve. 
Quantities of target in test samples were normalized to 18-s rRNA (PE ABI). 
 
RNA-Sequencing and Secretome Analysis 
mRNA sequencing was performed on control and dasatinib-resistant cells 
as previously described (140). Briefly, sequencing was performed at the 
University of Colorado Cancer Center (UCCC) Genomics and Microarray Core 






on the HiSeq2000 (single read 100 cycles). On average, 70 million reads per 
sample were obtained, with an average mapping of 98% to the hg19 reference 
genome using the tophat/cufflinks workflow as previously described (144). For 
secretome analysis, a gene list from the Secreted Protein Database (145) 
(http://spd.cbi.pku.edu.cn/) was extracted from the RNA-sequencing data of 




MMP activation was profiled by gelatin zymography where equal volumes 
of conditioned media mixed 1:4 with 5X non-reducing sample buffer (0.313 M 
Tris-HCL pH6.8, 10% SDS, 50% glycerol, 0.05% bromophenol blue) were loaded 
on 10% polyacrylamide gels with gelatin (Ready Gel ®, BioRad) and subjected to 
SDS-polyacrylamide gel electrophoresis. Recombinant MMP-2 and MMP-9 
(Biolegend) were activated by incubation with 1mM p-aminophenylmurcuric 
acetate (APMA) for 15 minutes and 4 hours, respectively, and used as positive 
controls. SDS was removed from the gels using a 25% Triton X-100 solution and 
gels were incubated at 37°C for 48 hours in incubation buffer (50mM Tris- HCl 
pH7.4, 10mM CaCl2, 0.02% NaN3). Gels were stained with 0.25% Coomassie 
Brilliant Blue and slowly destained to observe substrate cleavage. Gels were 
imaged using an AlphaImager Gel System where gelatinase activity was 
demonstrated as clear bands on dark background. Densitometric analysis of the 






In Vivo Orthotopic Mouse Model of Thyroid Cancer 
For the orthotopic murine model, BCPAP and 8505C cells (5 x 105 in 5 L) 
engineered to express a luciferase-IRES-GFP plasmid were injected into the 
right thyroid lobe of athymic nude mice (Harlan/Envigo: Athymic Nude-Foxn1nu; 
female, 6-8 week old), as previously described (141,146). Tumor establishment 
and progression was measured weekly by detection of bioluminescence with the 
Xenogen IVIS200 system (Caliper) in the University of Colorado Cancer Center 
(UCCC) Small Animal Imaging Core. Bioluminescence activity (photons/s) was 
quantitated using the Living Image 2.60.1 software (Igor Corp). 
Minimum/maximum thresholds were normalized to compare images using the 
same scale. Mice were randomized for treatment on day 10 based on 
bioluminescence activity and were treated with either PF-562,271 (50mg/kg) by 
oral gavage (7 d/wk) in 5% w/v Gelucire 44/14 (Gattefossé) in MiliQ water, or 
vehicle (5% 5% w/v Gelucire 44/14 in MiliQ water). Final thyroid tumor size was 
measured with calipers and volume was calculated using the following formula 
for an ellipsoid-like shape: tumor volume = (length X width X height)*0.5236. 
These studies were conducted in accordance with the animal protocol 
procedures approved by the Institutional Animal Care and Use Committee at the 
University of Colorado.  
 
In Vivo Intracardiac Injection Experimental Metastasis Model of Thyroid 
Cancer 
For the experimental metastasis murine model, athymic nude mice 





via intraperitoneal injection, and 5 minutes later each mouse was anesthetized 
using isofluorane. BCPAP-luc-IRES-GFP cells or 8505C-luc-IRES-GFP cells (105 
cells in 100 L PBS) were injected into the left ventricle using a 26-gauge needle, 
as previously described (141). Successful injection into the left ventricle was 
monitored by the pulsatile flow of red blood into the needle hub indicating correct 
placement, and by whole body bioluminescence immediately following injection 
(1 minute images). In the metastatic model, mice received PF-562,271 or vehicle 
(as detailed above), starting 2 days before intracardiac injection (pre-treatment), 
or on day 8 following randomization (post-treatment). Both treatment approaches 
were continued throughout the experiment. Metastatic progression was 
monitored weekly by IVIS imaging. Mice were sacrificed if more than 20% body 
weight was lost, and based on moribund criteria. For ex vivo imaging, mice were 
injected with D-luciferin (3 mg/mouse) before necropsy. Tissues of interest were 
excised, placed in 6-well tissue culture plates containing D-luciferin in PBS, and 
imaged for 5 seconds to 2 minutes. 
 
Immunohistochemistry  
Tumors were collected and fixed in 10% buffered-formalin. Samples were 
embedded in paraffin and sections were cut by the UCD Research Histology 
Shared Resource Core. Sections were stained with hematoxylin and eosin per a 
standardized protocol. Invasion was scored by a pathologist using the following 
criteria: 1 = Minimal:  Rare focal superficial invasion; 2 = Mild: Multifocal 
superficial invasion; 3 = Moderate: deep invasion; 4 = Severe: Extensive deep 





Immunohistochemistry (IHC) for Ki67 (Invitrogen #180191Z; 1:100) was 
performed and scored as percent of positive cells. CD34 (Abcam ab81289; 
1:500) staining was performed by the UCD Research Histology Shared Resource 
Core. Sections were examined under low magnification for representative areas 
of tumor. Three 20x fields were selected with the highest density of vessels. 
Vessels were counted and counts averaged to determine the mean vascular 
density (MVD). Phosphorylated Y397FAK (Abcam ab8298; 1:300) staining was 
performed and scored based on degree of expression (0 through 3). Staining for 
F4/80 was performed in collaboration with Traci Lyons lab at the University of 
Colorado and percent of F4/80 positive cells was quantified using Aperio 
Software (Leica Biosystems). Staining of phosphorylated Y861FAK and Total 
FAK was performed by UCD Histology Shared Resource Core. A pathologist 
analyzed the staining and scored intensity 0-3 (negative to strong) and quantified 
the proportion of cells positive (0-5: 0 to 100%). Staining localization, either 
nuclear or membranous, was also characterized.  
 
Second Harmonic Generation (SHG) Imaging 
 Paraffin-embedded sections were analyzed through second harmonic 
generation of light, using a confocal multiphoton microscope (Zeiss LSM 780 
System) at the University of Colorado Advanced Light Microscopy Core Facility. 
Images were acquired through a 20x magnification objective lens and analyzed 
with Zen software (Carl Zeiss). The tile-scan function was employed to visualize 
large sections of tumor and single-frame images for three different locations on 





autofluorescence and the presence of collagen was confirmed by SHG signal in 
the red fluorescence channel. SHG signal intensities were quantified for each 
tumor section using ImageJ (NIH).  
 
Statistical Analysis 
Data show the mean of at least 3 independent experiments ± standard 
deviation (SD) or standard error mean (SEM), as indicated. GraphPad Prism 
statistical software was used to perform the 2-tailed Student’s t-test and for 2-
way ANOVA analysis. Fold changes are calculated from mean values of each 
treatment group. For all statistical analyses, asterisks (*) indicates p≤0.05; ** = 











FAK EXPRESSION, NOT KINASE ACTIVITY, IS A KEY MEDIATOR OF 




Thyroid cancer is the most common endocrine malignancy accounting for 
~4% of all new cancer cases diagnosed in 2014 in the U.S. (147), and the 
incidence has been increasing (9). While the majority of patients respond well to 
standard-of-care therapy, including tumor resection and radioactive iodine, local 
recurrence occurs in up to 20% of patients (3). Patients with advanced thyroid 
cancer, including those diagnosed with advanced papillary thyroid cancer (PTC), 
anaplastic thyroid cancer (ATC), and those with distant metastases, have 
extremely reduced survival. Specifically, patients with advanced PTC have a 5-
year survival rate of 55% while patients with ATC, accounting for the most thyroid 
cancer related deaths, have a 1-year survival rate of only 20% (9). Unfortunately, 
there are limited effective therapy options for these patients (149).  
Approximately 70% of thyroid cancers exhibit aberrant activation of the 
Mitogen Activated Protein kinase (MAPK) pathway due to mutations in effector 
proteins, including B-Raf, Ras, and through RET/PTC rearrangements (149).  
Despite the importance of the MAPK pathway in thyroid cancer, MAPK-directed 
therapies have had limited efficacy thus far (9).  We have focused on the role of 
Src family kinases (SFKs), which are frequently overexpressed and activated in 
                                                 
1 Portions of this chapter were previously published in Molecular Cancer Research 2016 and are 






many tumor types (150). Src has been shown to promote multiple pro-
tumorigenic functions including proliferation, survival, and migration through 
activation of downstream pathways including phosphoinositide 3-kinase (PI3K), 
Stat-3, p130Cas, paxillin, and focal adhesion kinase (FAK) (151). FAK (PTK2) 
has been shown to physically and functionally interact with Src to promote a 
variety of cellular responses (32). Notably, our previous studies have shown that 
FAK phosphorylation at the Src-dependent phosphorylation site, Y861, correlates 
with Src inhibitor sensitivity in thyroid cancer cell lines in vitro and in vivo 
(141,142). 
Pathological studies have shown that FAK expression is deregulated in a 
number of cancers, including breast, colon, ovarian, pancreas, prostate, and 
others (152). In a previous study, FAK protein was observed to be overexpressed 
in a subset of PTC and ATC samples and correlated to a more invasive 
phenotype (115,116). We recently demonstrated that FAK is overexpressed in 
thyroid cancer cell lines, and in 10 out of 10 human PTC samples tested (142). 
We further showed that FAK is phosphorylated at Y861 in 5 out of 10 PTC 
samples (142). Accordingly, a study by Michailidi et al observed FAK expression 
in 25 out of 45 (75%) PTC samples and in 1 of 2 (50%) ATC samples (153). 
Phosphorylation of FAK at Y861 was more frequent in malignant compared to 
benign samples, and in PTC compared to hyperplasia samples, further 
supporting a role for Src and FAK signaling in thyroid cancer (153). 
FAK is a non-receptor tyrosine kinase, and is a key regulator of signaling 





as a kinase by phosphorylating multiple substrates. This dual-function protein 
allows for cross-talk between integrins and growth factor receptors to regulate 
cell proliferation, survival, migration, and invasion (154). Autophosphorylation of 
FAK at Y397 occurs upon association with integrins or growth factor receptors. 
This phosphorylation site creates a high-affinity binding site for SH2-domain 
containing proteins such as Src and PI3K (154), which is thought to lead to the 
phosphorylation of other FAK tyrosine residues, including Y576/577 located in 
the kinase domain, as well as Y407, Y861, and Y925, thereby creating binding 
sites for effector proteins of downstream pathways (155). FAK can signal to the 
MAPK and AKT pathways, however, it remains unclear how mutational activation 
of the MAPK and PI3K/AKT pathways affects FAK-dependent signaling 
(119,137). Finally, effector binding sites on FAK are found within the FERM 
domain and the proline-rich regions, which are important for paxillin and p130Cas 
binding to regulate cell motility, migration, and invasion (155). Taken together, it 
is becoming clear that FAK mediates multiple signaling pathways through both its 
kinase and scaffolding functions. Therefore, FAK may promote key pro-
tumorigenic processes through distinct kinase-dependent and kinase-
independent (scaffolding) mechanisms, and targeting these dual functions may 
provide new therapeutic strategies for cancer patients. 
Several small molecule inhibitors targeting FAK kinase activity have been 
developed and evaluated in both pre-clinical models and clinical trials. Recently, 
a phase I clinical trial with the FAK kinase inhibitor PF-562,271 (Pfizer) (acquired 





carcinoma, and castrate-resistant prostate cancer, where ~30% of patients 
demonstrated stable disease at first restaging imaging (156). Thus, providing 
support for further investigation of FAK as a promising therapeutic target. In 
addition, clinical trials with other FAK kinase inhibitors including GSK-2256098 
(Glaxo Smith Kline) and two drugs from Verastem, VS-6063 and VS-4718, 
originally PF-04554878 and PND-1186 respectively, are ongoing in patients with 
advanced ovarian cancer, solid tumors, and metastatic non-hematological 
malignancies (43,157). As noted above, because FAK can function 
independently of its kinase activity (by acting as a scaffold for protein-protein 
interactions), drugs that only target the catalytic activity of FAK may not be 
sufficient to block regulation of kinase-independent pro-tumorigenic responses 
(158).  As such, drugs that block the protein-protein interaction between effector 
proteins and FAK are currently being evaluated in pre-clinical models. These 
include small molecules that interrupt the interaction between FAK and VEGFR, 
IGFR-1, Mdm-2, and p53 (Cure FAKtor Pharmaceuticals) (157).  Therefore, in 
order to effectively target FAK clinically, a better understanding of FAK signaling 
is needed. Here we define the role of FAK expression and kinase activity, and 
demonstrate that FAK expression, not kinase activity, plays a key role in 










Inhibition of FAK Kinase Activity Versus FAK Expression Differentially Regulates 
Growth  
 
We have previously demonstrated that increased levels of FAK 
phosphorylation at the Src-dependent site, Y861 and the FAK 
autophosphorylation site, Y397, correlates with sensitivity to Src inhibition 
(141,142). To further define the role of FAK in thyroid cancer, we focused on cell 
lines with high (BCPAP) and low (8505C) sensitivity to Src inhibition, to 
specifically evaluate the kinase-dependent and –independent functions of FAK 
(141,142).  To define the role of kinase activity, we used the FAK kinase inhibitor, 
PF-573,228, to selectively inhibit FAK kinase activity. Figure 1A shows that while 
treatment with 0.1 M PF-573,228 has modest effects on pY397-FAK levels 
(~10-20% reduction), treatment with 1 M PF-573,228 resulted in decreased 
levels of phospho-FAK (pY397) in both BCPAP and 8505C cells (~40-50% 
reduction) (Figure 3.1A). Of note, complete inhibition of phosphorylation at 
pY397FAK was not observed at 1 M of PF-573,228, potentially due to continued 
phosphorylation of this site by upstream kinases, as previously observed in other 
tumor models (38,159,160). Additionally, no compensatory increase in the 
phosphorylation of the FAK-related kinase, PYK2, was observed in either cell line 
with PF-573,228 treatment (data not shown). We next evaluated the effects of 
FAK kinase inhibition on Src activity, which has been coupled to FAK activation 
in other cellular contexts.  Interestingly, Src phosphorylation at the activating 





inhibition in either the BCPAP or 8505C cells (Figure 3.1A).  Consistent with the 
lack of regulation of Src, we show that phosphorylation of the Src-dependent 
sites, Y861FAK and Y925FAK, are not altered in response to PF-573,228 
treatment, indicating that Src-dependent phosphorylation of these sites is not 
disrupted by inhibition of FAK autophosphorylation (Figure 3.1A).  
 
Figure 3.1: FAK kinase activity is dispensable for adherent growth but 
mediates anchorage-independent growth. (A) BCPAP and 8505C cells were 
treated with the indicated concentration of FAK inhibitor PF-573,228 for 24 
hours. Blots shown are representative of 3 independent experiments. (B) 
Viability of BCPAP and 8505C cells treated with 1µM PF-573,228 for 6 days 
was normalized to DMSO-treated cells, set to 100%. Results are % viable cells 
per mL  ± SD of 3 experiments performed in triplicate BCPAP PF-573: n.s; 
8505C PF-573: n.s.).  (C) Colonies of BCPAP and 8505C cells treated with 1µM 
PF-573,228 in soft agar were allowed to form for 20 days and normalized to 
DMSO-treated cells, set to 100%. Results shown are percent of colony 
formation ± SD of 3 independent experiments performed in duplicate (BCPAP 






Further evaluation of p130Cas, a downstream target of FAK and Src (161), 
showed no consistent regulation in response to PF-573,228 treatment (Figure 
3.1A).  However, we have previously shown that phosphorylation of paxillin and 
p130Cas is inhibited in response to Src inhibition (141) (See Figure 4.3), 
indicating that p130Cas is a target of Src and not FAK. Together these results 
indicate that while inhibition of FAK kinase activity with PF-573,228 reduces FAK 
autophosphorylation, this does not disrupt the activity of Src, or the 
phosphorylation of the Src-dependent sites pY861 or pY925. Furthermore, our 
results show that p130Cas is likely a target of Src, and not FAK, in thyroid cancer 
cells, consistent with recent studies in breast cancer using a structurally distinct 
FAK kinase inhibitor, PND-1186 (162).  
Finally, we evaluated the regulation of ERK and AKT signaling in response 
to FAK kinase inhibition, given the important role of these oncogenic pathways in 
thyroid cancer.  In addition, both the BCPAP and 8505C cells express the BRAF 
V600E mutation.  Figure 3.1A shows that FAK kinase inhibition does not affect 
phospho-ERK1/2 levels, consistent with mutant-BRAF driving ERK activity in 
these cells. Interestingly, phosphorylation of AKT (at S473) was decreased in 
response to FAK inhibition (Figure 3.1A) indicating FAK may rely on AKT for 
signaling responses.   
To begin to define the role of FAK kinase activity in tumorigenic 
processes, the effects of FAK kinase inhibition on adherent growth was 
evaluated by cell viability assays. We observed that FAK kinase activity is 





treatment with 1M PF-573,228 did not significantly inhibit cell growth (Figure 
3.1B).  These results are consistent with other tumor models, where FAK kinase 
activity has modest effects on adherent cell growth (126,162).  In addition, no 
enhanced sensitivity to FAK inhibition was observed in the presence of 
fibronectin, suggesting that integrin activation does not alter dependency on FAK 
activity in thyroid cancer cell lines (Figure 3.2). Of note, dual inhibition of FAK 
and PYK2 by treatment with PF-562,271 (Pfizer), also had minimal effects on 
adherent growth of thyroid cancer cells in vitro (See Figure 4.14), suggesting that 
compensatory PYK2 signaling is not important.  
We next evaluated the role of FAK on anchorage-independent growth, 
where FAK scaffolding and kinase activity have been shown to play an important 
role in other tumor types,  including ovarian and breast cancer (91,124,163).  
Figure 3.2: Sensitivity to FAK inhibition is unaltered in response to 
fibronectin. BCPAP and 8505C cells were plated in 96-well plates with or 
without fibronectin and exposed to the indicated concentrations of PF-
573,228 for 5 days. Results shown are mean percent growth ± SD of 2 
experiments performed in triplicate. (TC-treated = tissue-culture treated; 






We performed colony formation assays where the BCPAP and 8505C cells were 
exposed to 1 M PF-573,228 for 20 days. While FAK kinase inhibition did not 
affect adherent cell growth (Figure 3.1B), Figure 3.1C shows that FAK kinase 
inhibition with PF-573,228 effectively inhibited colony formation by ~60% in the 
BCPAP cells (p≤0.05, t-test), but did not significantly affect colony formation in 
the 8505C cells (~20%: p=n.s., t-test). We also tested the effects of FAK kinase 
inhibition on additional thyroid cancer cell lines under adherent and anchorage 
independent conditions.  Figure 3.3A shows that with the exception of the C643 
and TPC1 cells, the majority of thyroid cancer cell lines tested are relatively 
resistant to FAK kinase inhibition under adherent conditions (IC50 > 1 M).   
 
Figure 3.3: Sensitivity to FAK inhibition under anchorage-independent 
conditions in a panel of thyroid cancer cells. (A) Viability of thyroid cancer 
cells treated with 1µM PF-573,228 for 6 days was normalized to DMSO-treated 
cells, set to 100%. Results are % viable cells per mL ± SD of at least 2 
experiments performed in triplicate (t-test: C643, K1, THJ11T:  p≤0.05; TPC1 
PF-573: p≤0.01; all others p=n.s.). (B) Colonies of thyroid cancer cells treated 
with 1µM PF-573,228 in soft agar were allowed to form for 20 days and 
normalized to DMSO-treated cells, set to 100%. Results shown are percent of 
colony formation ± SD of 2 independent experiments performed in duplicate (t-






Enhanced sensitivity to PF-573,228 treatment under anchorage-independent 
conditions was also observed in the RAS-mutant C643 cells, while the remaining 
thyroid cancer cell lines exhibited similar sensitivities in adherent and anchorage-
independent conditions (Figure 3.3A and 3.3B). Together these data indicate that 
for certain thyroid cancer cell lines, FAK activity is more important in a three-
dimensional, anchorage-independent environment. However, the precise 
mechanisms mediating this response remain under investigation, but appear to 
be independent of oncogene mutation status.  
To begin to define the role of both FAK scaffolding and kinase functions in 
thyroid tumorigenesis, a genetic approach was used to generate cells lacking 
FAK protein expression. Specifically, two independent shRNA constructs 
targeting FAK (shFAK-1 and shFAK-2) or a scrambled control were introduced 
into cells via lentiviral transduction. After short-term selection, Western blot 
analysis showed efficient knockdown of total FAK in both the BCPAP and 8505C 
cells, which corresponds to a loss of pY397FAK (Figure 3.4A). Similar to 
inhibition of FAK kinase activity (Figure 3.1A), pY416Src levels were not 
consistently decreased by expression of shFAK, indicating that Src 
phosphorylation is not dependent on FAK expression or activity (Figure 3.4A).  In 
addition, pAKT levels were not consistently regulated by knockdown of FAK 
expression.  Finally, phospho-ERK1/2 levels were not affected by knockdown of 
FAK expression, consistent with ERK being a target of oncogenic BRAF, but not 







In order to define the role of FAK expression on adherent cell growth, 
growth of BCPAP and 8505C cells expressing shFAK or scrambled control was 
assessed by Vi-CELL counting (Figure 3.4B). FAK knockdown resulted in ~50-
65% growth inhibition in the BCPAP cells, and ~50% inhibition of 8505C cells 
(BCPAP shFAK1: p≤0.01, shFAK2: p≤0.05, t-test; 8505C shFAK1: p≤0.01, t-test; 
Figure 3.4: FAK expression mediates adherent and anchorage-
independent growth. (A) BCPAP and 8505C cells expressing shRNA targeting 
FAK or a scrambled control were analyzed via Western blot. Blots are 
representative of 3 independent experiments (B) Viability of BCPAP and 8505C 
cells expressing shFAK was normalized to scrambled expressing cells, set to 
100%. Results are % viable cells per mL ± SD of 3 experiments performed in 
triplicate (BCPAP shFAK1: p≤0.01 and shFAK2: p≤0.05; 8505C shFAK1 and 
shFAK2: p≤0.01).  (C) Colonies of BCPAP and 8505C cells expressing shFAK 
were plated in soft agar, allowed to form colonies for 20 days and normalized to 
scrambled cells, set to 100%. Results shown are percent of colony formation ± 
SD of 3 independent experiments performed in duplicate (BCPAP shFAK1 and 






shFAK2: p≤0.01, t-test). Both FAK kinase activity and expression have been 
shown to promote anchorage independent growth in certain cellular contexts 
(71,128). As shown in Figure 3.4C, the BCPAP cells are extremely sensitive to 
the loss of FAK expression, with a reduction in colony formation of ~80-90% 
(p≤0.0001, t-test). Colony formation was also significantly decreased by ~60-80% 
in the 8505C cells with FAK protein knockdown (shFAK1: p≤0.0001; shFAK2: 
p≤0.01, t-test). Taken together with the inhibition of FAK kinase activity, these 
results indicate that both adherent and anchorage-independent growth of thyroid 
cancer cells is predominately regulated by FAK protein expression (Figure 3.1B, 
3.1C, 3.4B, and 3.4C). 
 
Tumor Growth is Differentially Regulated by FAK Kinase Activity and Expression. 
 We next evaluated the role of FAK kinase activity versus expression in 
tumor establishment and growth using the orthotopic thyroid cancer model 
(141,164–168).  To assess the role of FAK kinase activity, BCPAP or 8505C cells 
engineered to stably express a luciferase-IRES-GFP plasmid were injected into 
the right thyroid gland of athymic nude mice, as previously described (141). 
Tumor establishment and progression was monitored by detection of 
bioluminescence. Mice were randomized after tumor establishment on day 10 
and treated daily with the orally available and structurally related FAK/PYK2 
kinase inhibitor PF-562,271 (50mg/kg) (128,169). Using this model, we observed 
significant inhibition of BCPAP orthotopic tumor growth after 14 days of FAK 
inhibitor treatment (day 24: p≤0.01, t-test), as compared to the vehicle-treated 




64   








Figure 3.5: PTC orthotopic tumor growth is significantly reduced with FAK 
kinase inhibition. Mice were injected with BCPAP cells, randomized, and 
treated on day 10 with 50 mg/kg of PF-562,271 or vehicle for 29 days. (A) 
BCPAP tumor growth overtime was observed via bioluminescence signaling 
(day 24, p≤0.01; day 29 p≤0.01; t-test.). Results shown are mean 
bioluminescence signal (photons/second) per group ± SEM at the indicated time 
points. (B) Representative bioluminescence images for BCPAP are shown. (C) 
BCPAP tumors were collected at day 29 and size was measured with calipers. 
The final tumor volumes were calculated (p≤0.05, t-test). (D) IHC staining on 
BCPAP tumors was performed on sections of each tumor and scored as degree 
of staining by a pathologist. Results are degree of staining ± SEM (p≤0.05, t-
test). (E) H&E staining was performed on BCPAP tumor sections and the 
percent of invasion was scored and calculated by a pathologist. Results are 
invasion scores ± SEM (p = n.s). (F) Representative images from IHC staining 
of pY397FAK (left) and H&E (right) or vehicle and PF-271 treated tumors are 
shown (200x magnification). H&E of vehicle-treated tumor shows invasion of 
poorly differentiated carcinoma into striated muscle Small arrows demonstrates 
muscle. H&E of PF-271-treated tumor shows invasion of poorly differentiated 
carcinoma into esophagus-adjacent muscle. Small arrows demonstrate muscle.  
Arrowhead demonstrates esophageal squamous mucosa. (Hematoxylin-eosin, 






in ~40% reduction in BCPAP orthotopic final tumor volume, average of 125.58 ± 
87.03 mm3, while vehicle-treated control mice developed orthotopic tumors with 
an average volume of 213.34 ± 95.12 mm3 ( p≤0.05, t-test; Figure 3.5C). Finally, 
we observed a significant decrease in pY397FAK levels in FAK inhibitor-treated 
mice compared to vehicle-treated controls by immunohistochemical analysis 
(Figure 3.5D and 3.5F; p≤0.05, t-test). 
 Like the BCPAP (PTC) tumors, we also observed a significant inhibition of 
tumor growth in the 8505C orthotopic model 14 days after treatment with PF-
562,271 (day 24: p≤0.05, t-test) (Figure 3.6A and 3.6B). While a significant 
difference in bioluminescence imaging was not observed at the final time point, 
average final tumor volumes for vehicle-treated mice versus PF-562,271 treated 
mice were 84.25 ± 19.22 mm3 and 55.86 ± 35.03 mm3, respectively, with a 
decrease in tumor growth of 34% (p≤0.05, t-test) (Figure 3.6C), indicating PF-
562,271 treatment results in significant inhibition of tumor growth. We also 
observed that expression of pY397FAK was significantly decreased in the 8505C 
tumors treated with PF-562,271 compared to vehicle-treated controls (Figure 
3.6D and 3.6F: p≤0.01, t-test). 
 Due to the important role of FAK signaling in tumor invasion (158), we 
next evaluated whether inhibition of FAK kinase activity would disrupt this 
process. Interestingly, we did not observe a significant difference in invasion with 
FAK inhibitor treatment in the BCPAP or 8505C orthotopic models (Figure 3.5E 
and 3.6E). Consistently, in vitro invasion assays using Matrigel-coated transwell 
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Figure 3.6: ATC orthotopic tumor growth is reduced with FAK kinase 
inhibition. Mice were injected with 8505C cells, randomized, and treated on 
day 10 with 50 mg/kg of PF-562,271 or vehicle for 30 days. (A) 8505C tumor 
growth overtime was observed via bioluminescence signaling (day 24, p≤0.05, 
t-test). Results shown are mean bioluminescence signal (photons/second) per 
group ± SEM at the indicated time points. (B) Representative bioluminescence 
images for 8505C are shown. (C) 8505C tumors were collected at day 30 and 
size was measured with calipers. The final tumor volumes were calculated 
(p≤0.05, t-test). (D) IHC staining on 8505C tumors was performed on sections 
of each tumor and scored as degree of positive staining by a pathologist. 
Results are degree of staining ± SD (p≤0.01, t-test). (E) H&E staining on 8505C 
tumors was performed on sections of each tumor.  The percent of invasion was 
scored and calculated by a pathologist. Results are invasion scores ± SEM (p 
= n.s). (F) Representative images from IHC staining of pY397FAK (left) and 
H&E (right) of vehicle and PF-271 treated tumors are shown (200x 
magnification). H&E of vehicle-treated tumor shows invasion of poorly 
differentiated carcinoma through cartilage of trachea (large arrow). H&E of PF-
271-treated tumor shows invasion of poorly differentiated carcinoma through 
cartilage of trachea (large arrow). Small arrows demonstrate numerous mitotic 






was also not significantly inhibited (Figure 3.7A). We next evaluated the effects of 
FAK kinase inhibition on proliferation in vivo.  Similar to the effects of FAK kinase 
inhibition on in vitro cell growth (Figure 3.1B), Ki67 staining of FAK inhibitor 
treated tumors did not reveal significant change in proliferation compared to 
vehicle tumors (Figure 3.8A and 3.8B).  Additionally, FAK has been shown to 
play a key role in angiogenesis through its function in endothelial cells (170).  
However, CD34 staining, a marker of mouse endothelial cells, revealed no 
change in angiogenesis in the orthotopic tumors in response to FAK kinase 
inhibition (Figure 3.9A and 3.9B). Together, these data indicate that the kinase 
activity of FAK contributes to the pro-tumorigenic processes necessary for thyroid 




Figure 3.7: FAK kinase inhibition and FAK expression do not regulate 
thyroid cancer invasion in vitro. BCPAP and 8505C cells exposed to (A) 
1uM PF-573,228 for 24 hours or those expressing (B) shFAK were assessed 
for migration through Matrigel-coated transwell chambers. Invaded cells 
treated with DMSO control or those expressing scrambled control were set to 
100%. Results are percent inhibition of invasion ± SEM of at least 3 








 Given the key role for FAK expression in the regulation of both adherent 
and anchorage independent thyroid cancer cell growth (Figure 3.5B and 3.4C), 
we next evaluated the role of FAK expression in thyroid tumor establishment and 
progression in vivo. Specifically, BCPAP or 8505C cells expressing either shFAK 
or scrambled control were injected into the thyroid glands of nude mice 
orthotopically, as described above. Representative images of mice injected with 
BCPAP cells expressing scrambled control or shFAK are shown in Figure 3.10B. 
Notably, tumor establishment was inhibited in the BCPAP shFAK group by 
bioluminescence (Figure 3.10A and 3.10B), and no tumors were present at the 
time of dissection (Figure 3.10C).  We observed a robust inhibition of 8505C 
tumor growth with shRNA knockdown of FAK, but in contrast to the BCPAP-
derived tumors, the 8505C-derived tumors expressing shFAK were able to 
establish (Figure 3.10D and 3.10E) and grow to an average final tumor volume of  
Figure 3.8: Proliferation of PTC and ATC orthotopic tumors is not affected 
by FAK inhibition in vivo. IHC staining on (A) BCPAP and (B) 8505C 
orthotopic thyroid tumors for Ki67, a marker of cellular proliferation, was 
performed on sections of each tumor.  The percent of Ki67 positive cells was 






19.98 ± 9.89 mm3, representing an ~80% average reduction in tumor volume 
compared to the scrambled control tumors (p≤0.0001, t-test; scrambled average 
final tumor volume of 122.5 +/- 45.67 mm3; Figures 3.10F). In contrast to FAK 
kinase inhibition (Figures 3.5E and 3.6E), we observed that FAK knockdown 
significantly inhibited invasion in the 8505C orthotopic model (Figure 3.10G and 
3.10H, p≤0.01, t-test), despite having no effect on invasion in vitro (Figure 3.7B). 
However, in contrast to our in vitro data (Figure 3.4B), FAK depletion did not 
significantly affect cellular proliferation in vivo, as measured by Ki67 staining 
(Figure 3.11). Taken together, these data indicate that FAK expression plays a 
key role in tumor establishment and/or progression, as well as invasion, of 
thyroid cancer cells in vivo and that FAK kinase activity may be more important 
for tumor progression.  
Figure 3.9: Angiogenesis of PTC and ATC orthotopic tumors is not 
affected by FAK inhibition in vivo. IHC staining on (A) BCPAP and (B) 8505C 
orthotopic thyroid tumors for CD34, an endothelial cell marker, was performed 
on sections of each tumor.  Sections were examined under low magnification 
for representative areas of tumor. Three 20x fields were selected with the 
highest density of vessels. Vessels visualized by CD34 IHC staining were 
counted and counts averaged to determine the mean vascular density (MVD). 








Figure 3.10A: Loss of FAK expression significantly reduces tumor 








Figure 3.10A: Loss of FAK expression significantly reduces tumor 
growth in ATC and prevents tumor establishment in PTC orthotopic 
models. Mice were injected with BCPAP or 8505C cells expressing either 
shFAK (shFAK1) or scrambled control shRNA. BCPAP (A) and 8505C (D) 
tumor growth was monitored overtime via bioluminescence imaging (BCPAP: 
day 7, p≤0.05; day 21, p≤0.001; day 28, p≤0.01; day 35, p≤0.05; t-test. 8505C: 
day 7, p≤0.05; day 14, p≤0.001; day 21, p≤0.05; day 28, p≤0.01; t-test). Results 
shown are mean bioluminescence signal (photons/second) per group ± SEM 
at the indicated time points. Representative bioluminescence images for 
BCPAP shFAK and scrambled tumors (B) and 8505C shFAK and scrambled 
tumors (E) are shown. Tumors were collected upon dissection (BCPAP = day 
35; 8505C = day 28) and final tumor volumes for BCPAP (C) and 8505C (F) 








Figure 3.10B: Loss of FAK expression significantly reduces tumor 
growth in ATC and prevents tumor establishment in PTC orthotopic 
models. Mice were injected with BCPAP or 8505C cells expressing either 
shFAK (shFAK1) or scrambled control shRNA. (G) H&E staining was 
performed on sections of 8505C shFAK and scrambled orthotopic thyroid 
tumors. Invasion was scored and calculated by a pathologist. Results are 
invasion scores ± SEM (p≤0.0001, t-test). (H) Representative images are 
shown of H&E staining. H&E of scrambled-expressing tumor shows invasion 
of poorly differentiated carcinoma into trachea. Small arrows demonstrate 
salivary gland. Arrowhead demonstrates tracheal cartilage. (Bottom) H&E of 
shFAK-expressing tumor with arrows demonstrating invasion of tumor cells 






Inhibition of FAK Kinase Activity Reduces PTC Metastasis In Vivo but Increases 
Metastasis in an ATC Model. 
 
 FAK has been shown to play an important role in metastasis 
(91,120,129,171), but how FAK contributes to metastatic process, and whether 
pharmacological inhibition of FAK kinase activity will prevent or inhibit the 
development of metastases is not clear.   In order to study the role of FAK in the 
development of distant metastases, we employed an intracardiac injection 
experimental metastasis model, which models the late stages of metastasis, 
including intravasation and organ colonization, and allows for the analysis of 
systemic tumor formation.  We first asked whether FAK kinase inhibition would 
prevent the development of systemic tumor formation using a pretreatment 
approach, where mice were dosed with PF-562,271(50mg/kg) daily by oral 
gavage, two days before tumor cell injection, and treatment was continued 
Figure 3.11: Proliferation of shFAK-expressing 8505C orthotopic tumors 
is not significantly inhibited.  Ki67 staining of 8505C shFAK and Scrambled 
orthotopic thyroid tumors was performed. Proliferation was measured by the 
percent of Ki67 positive cells scored by a pathologist. Results are % Ki67 ± 






throughout the experiment. The one-minute images shown in Figure 3.12B 
validate successful left ventricle injection and bioluminescent cell dissemination 
throughout the body. Weekly bioluminescence imaging of the BCPAP tumors 
shows that tumors treated with PF-562,271 exhibited a ~2-fold reduction in 
overall tumor burden compared to the vehicle treated counterparts (p≤0.0001, 
ANOVA; Figure 3.12A and 3.12B), indicating that this pretreatment treatment 
approach has the potential to delay metastatic progression in this model.       
 
Figure 3.12: FAK kinase inhibition reduced PTC metastatic burden in vivo. 
Mice were pretreated with PF-562,271 (50mg/kg, 7d/w) 2 days prior to injection. 
Mice were injected with BCPAP cells. (A) Bioluminescence detection monitored 
metastatic progression over time (p≤0.0001; ANOVA). Results shown are mean 
bioluminescence signal (photons/second) per group ± SEM at the indicated time 
points. (Final total metastatic burden: Control = 5.74x108 ± 2.47x108 p/s; PF-271 
treatment = 3.12x108 ± 2.10x108 p/s). (B) Representative bioluminescence 
images show 1 minute after injection to demonstrate dissemination. Ventral and 






To determine the role of FAK kinase activity in ATC metastasis, 8505C cells 
expressing luciferase were evaluated using the same pretreatment treatment 
approach described in Figure 3.12, where mice were treated with PF-562,271 
two days before tumor cell injection, and treatment was continued throughout the 
Figure 3.13: FAK kinase inhibition significantly enhances ATC metastatic 
burden in vivo using a pretreatment approach. Mice were injected with 
8505C cells and either (A) pretreated with PF-562,271 (50mg/kg, 7d/w) 2 days 
prior to injection or (B) treated 8 days after injection (post-treat). 
Bioluminescence detection monitored metastatic progression over time (Pre-
treatment: day 7, p≤0.01; day 14, p≤0.05; day 21, p≤0.05; day 35, p≤0.001; t-
test. Post-treatment: day 35, p≤0.01; t-test). Results shown are mean 
bioluminescence signal (photons/second) per group ± SEM at the indicated 
time points. (Final total metastatic burden of vehicle group = 1.83x109 ± 
1.04x109 p/s; PF-271 pretreatment = 4.21x109 ± 2.16x109; PF-271 post-
treatment = 4.98x108 ± 1.73x108 p/s). (C) Representative bioluminescence 
images show 1 minute after injection to demonstrate dissemination through the 






experiment. Successful left ventricle injection of 8505C cells is shown in Figure 
3.13C (1 minute images).  Surprisingly, weekly imaging revealed a significant 
1.5-fold increase in total tumor burden with this FAK inhibitor pretreatment 
approach (day 7: p≤0.01, day 14: p≤0.05, day 21: p≤0.05, day 35: p≤0.001; t-test; 
Figure 3.13A and 3.13C). The increase in 8505C tumor formation using the 
pretreatment approach was observed in two different experiments, and this data 
is combined in Figure 3.13A.  Due to the unexpected increase in tumor burden in 
response to PF-562,271 pretreatment, we asked if this was due to the timing of 
PF-562,271 treatment.  Therefore, we used a post-treatment approach, where 
PF-562,271 (50mg/kg) was administered 8 days after intracardiac injection of the 
8505C cells, when tumors have established. Interestingly, the post-treatment 
approach with PF-562,271 resulted in a 3.7-fold decrease in overall tumor burden 
(p≤0.01, t-test), with final tumor burden of 1.83x109 ± 1.04x109 photons/second 
for vehicle-treated mice and 4.98x108 ± 1.73x108 photons/second for the post-
treatment group (Figure 3.13B and 3.13C). Together, these results indicate that 
the response of the 8505C tumors is dependent on the timing of FAK inhibitor 
treatment, where the pretreatment approach increases overall tumor burden, and 
the post-treatment approach reduces overall tumor burden. Interestingly, analysis 
of ex vivo imaging shows an increase in metastasis to the bone of PF-562,271 
pre-treated mice compared to either vehicle-treated or PF-562,271 post-treated 
mice (Figure 3.14). With this in mind, we next tested the effects of a FAK inhibitor 





variety of ECM proteins. For this, cells were allowed to attach to an ECM array in  
the presence of drug after pre-treatment with FAK inhibitor PF-573,228 for 24 
hours. Inhibition of FAK kinase activity with PF-573,228 had either no effect, or 
significantly decreased the ability of the BCPAP cells to attach to ECM (Figure 
3.15; Collagen II and Vitronectin: p≤0.05). Consistent with our in vivo metastasis 
model, PF-573,228 increased the attachment of 8505C cells to many of the ECM 
proteins including fibronectin and collagen I, II, and IV (Figure 3.15; collagen I, II 
and fibronectin:  p≤0.05; collagen IV: p≤0.01). Taken all together, these results 
suggest that the differential responses to FAK inhibition on metastasis in vivo 
may be controlled by the role of FAK in mediating cellular adhesion.   
Figure 3.14: Location of metastases formed with PF-562,271 treatment.   
Bioluminescence images were taken of anatomic structures ex vivo upon 
dissection. Positive or negative bioluminescent signal from each location was 
recorded for each mouse. The number of metastases to the bone for each 
treatment group was quantified. Results shown are number of metastases per 







FAK Expression Regulates Thyroid Cancer Metastasis.  
 To determine the role of FAK expression in metastasis, cells expressing 
shFAK and a scrambled control shRNA were tested in the experimental 
metastasis model, as described above (Figures 3.12 and 3.13). Because FAK 
expression abolished tumor establishment in an orthotopic model of PTC (Figure 
3.10A-C), the experimental metastasis model was employed only in the 8505C 
(ATC) cells.  Consistent with the role of FAK expression in adherent and 
anchorage independent growth (Figure 3.4B-C), as well as orthotopic tumor 
growth (Figure 3.10A-F), overall tumor formation was significantly inhibited (20.6-
fold reduction) in mice injected with 8505C shFAK expressing cells as compared 
to cells expressing scrambled shRNA (Figure 3.16A-B; p≤0.001; ANOVA). These 
results indicate that FAK expression plays a key role in the development and/or 
progression of metastases. 
 
Figure 3.15: FAK inhibition differentially regulates adhesion to ECM 
proteins. (A) BCPAP and (B) 8505C cells were pre-treated with either 1uM PF-
573,228 or DMSO for 24 hours prior to exposure to an ECM array. Cells were 
allowed to attach for 2 hours in the presence of DMSO or PF-573,228. Attached 
cells were determined by measuring colorimetric absorbance at 570nm. Results 







There are currently limited effective therapies for patients with advanced thyroid 
cancer, especially those with distant metastases (149). We have previously 
shown that FAK is overexpressed and activated in thyroid tumors, as well as in 
cell lines derived from advanced thyroid cancer patients (142).  However, it is 
unclear how the functions of FAK mediate thyroid cancer, and whether the kinase 
or scaffolding functions of FAK are more important.  Inhibitors targeting the 
kinase activity of FAK have provided an opportunity to directly test the role of 
FAK kinase activity and are currently being tested in clinical trials (156). Herein, 
we provide evidence that FAK expression versus kinase functions play distinct 
Figure 3.16: shFAK expression reduces metastatic tumor burden. Mice 
were injected with 8505C cells expressing either scrambled shRNA or shFAK. 
(A) Bioluminescence detection monitored metastatic progression over time. 
Results shown are mean bioluminescence signal (photons/second) per group ± 
SEM at the indicated time points. (Total metastatic burden: scrambled group = 
1.72x1010 ± 1.29x1010 p/s; shFAK = 8.31x108 ± 2.77x108 p/s (p≤0.001; 
ANOVA)). (B) Representative bioluminescence images show 1 minute after 
injection to demonstrate dissemination through the body. Ventral and dorsal 






roles in thyroid cancer (Table 3.1). Furthermore, we identify FAK expression as 
critical for thyroid cancer growth and metastasis, providing a new molecular 
target for advanced thyroid cancer.  
 
 
In this study, we show that inhibition of FAK kinase activity with the 
selective small molecule inhibitor, PF-573,228, results in the inhibition of FAK 
Y397 autophosphorylation, without inhibition of p130Cas or Src phosphorylation.  
While these results are somewhat surprising, they are consistent with recent 
studies in breast cancer using the PND-1186 FAK kinase inhibitor (162).  In 
addition, we did not observe regulation of ERK1/2 in response to inhibition of 
FAK kinase activity or expression (Figure 3.1A and 3.4A), indicating that FAK 
does not regulate this oncogenic pathway in thyroid cancer. Consistent with this, 
we have not observed a correlation between sensitivity to FAK kinase inhibition 
and mutational status (BRAF, RAS, or RET/PTC; Figure 3.3 and data not 
shown). However, we did observe FAK-mediated regulation of AKT in response 
to FAK kinase inhibition (Figure 3.1A), although, changes in AKT did not 





correlate with response to growth inhibition (Figures 3.1B and 3.1C), indicating 
other mechanisms are involved.  Thus, the precise pathways regulated by FAK in 
thyroid cancer are currently not clear, but likely involve noncanonical signaling 
pathways, including p38, as observed in breast cancer (169).    
In addition to distinct signaling mechanisms, our results demonstrate that 
FAK kinase and expression regulate distinct processes in thyroid cancer, and 
FAK expression is the critical mediator of pro-tumorigenic processes. 
Specifically, adherent growth in both the BCPAP and 8505C cells was regulated 
predominantly by FAK expression, as FAK knockdown via shRNA displayed ~60-
80% growth inhibition, while inhibition of kinase activity with PF-573,228 had 
minimal effects (Figure 3.4B and 3.1B). shRNA depletion of FAK resulted in a 
significant loss of colony formation of both the BCPAP and 8505C cells (Figure 
3.4C).  Interestingly, while FAK kinase inhibition had limited effects under 
adherent conditions (Figure 3.1A and 3.3A), inhibition of kinase activity 
decreased colony formation by 20-80% (Figure 3.1C and 3.3B). These results 
are consistent with other tumor types, where inhibition of FAK kinase activity has 
had limited effects on proliferation under adherent growth conditions, but more 
striking affects under nonadherent conditions (162). The modest effects of FAK 
kinase inhibition are likely not due to compensatory upregulation of the related 
PYK2, as we did not observe an increase in total or phosphorylated PYK2 levels 
in response to FAK kinase inhibition (data not shown).  
The results of our in vivo studies are consistent with our in vitro data, and 





thyroid tumor progression (Figure 3.5 and 3.6). These in vivo results are also 
consistent with studies in other tumor types, including  breast, pancreas, and 
prostate cancer, where inhibition of FAK kinase activity results in modest 
inhibition of tumor development (128,129,162).  In these models, the effects of 
FAK kinase inhibition have been attributed to attenuated survival signaling 
(through AKT), increased apoptosis, and altered expression of cytokines such as 
IL-6, which may impact tumor progression through effects on both tumor and 
stromal cells (129,162,172). In contrast to FAK kinase inhibition, FAK knockdown 
completely blocked tumor establishment/progression in the BCPAP orthotopic 
model (Figure 3.10A-C), and robustly inhibited tumor progression in the 8505C 
orthotopic model (Figure 3.10D-F).  Similar results were observed in the 
metastatic model, suggesting that FAK expression is critical for tumor 
establishment and/or progression (Figure 3.16).  Genetic studies targeting FAK 
have also revealed an important role for FAK in apoptosis, and that FAK is 
necessary for extravasation (119). While the precise mechanisms regulating 
tumor growth and establishment in response to FAK inhibition in thyroid cancer 
are not clear, inhibition of FAK kinase activity or expression does not affect 
cancer cell proliferation or microvessel density (Figure 3.8 and 3.9).  Future 
studies will be needed to evaluate anti-tumor responses at earlier time points to 
assess the contribution of apoptosis and other processes that may affect tumor 
establishment, such as cytokine expression and AKT signaling. 
In our metastasis studies, paradoxically, we found that pretreatment of 





formation in the 8505C model, while a post-treatment approach decreased tumor 
burden (Figure 3.13). These data indicate that while inhibition of FAK kinase 
activity can exhibit anti-tumor and anti-metastatic activity, under certain treatment 
conditions, may promote tumor formation. Along these lines, recent evidence 
suggests a non-linear function of FAK expression where homozygous depletion 
of endothelial FAK inhibits angiogenesis and decreases final tumor volume, while 
FAK-heterozygous mice have enhanced tumor angiogenesis and increased 
tumor volumes (172). This phenotype was associated with increased AKT and 
MAPK signaling, providing a potential mechanism for enhanced cell survival and 
migration. Interestingly, the results obtained from the FAK-heterozygous mice 
were phenocopied using FAK kinase inhibitors (172). In addition, other studies 
have shown that FAK kinase activity negatively regulates invadopodia activity, 
thus inhibition of FAK can actually increase invasion (173,174).  Given this 
complicated role of FAK, it remains possible that inhibition of FAK kinase activity 
may provide an advantage for cancer cell survival and invasion, resulting in 
enhanced metastasis, as observed here.  
Consistent with our metastasis model, attachment of BCPAP and 8505C 
to ECM proteins was differentially regulated by pre-treatment with the FAK 
inhibitor PF-573,228 in vitro (Figure 3.15). FAK regulates cell adhesion and 
adhesion strength through integrin activation and binding, which is dependent on 
an intact Y397 residue, suggesting a potential role for both FAK scaffold and 
kinase activity in this process. Interestingly, the effects of FAK on integrin 





recruitment to focal adhesions in a time-dependent manner (175). In addition, 
FAK kinase activity and subsequent Src association is necessary for focal 
adhesion development and maturation, and therefore inhibition of FAK may 
regulate these events (176). While studies on the direct effects of FAK kinase 
activity on the recruitment and regulation of proteins involved in focal adhesion 
formation, including paxillin, viniculin and talin, are lacking, regulation may be a 
possibility due to the complexity of FAK functions and therefore requires further 
investigation.  Another more general, potential mechanism for the differential 
ECM adhesion may be through the formation of F-actin rich microtentacles, 
which have been shown to be regulated by c-Src and mediate cell attachment. c-
Src activation induces invadapodia formation but interestingly, inhibition of c-Src 
increases microtentacle formation and enhanced the capillary retention of 
circulating tumor cells in vivo and the rapid re-attachment of suspended cells in 
vitro (177). As FAK and Src activity are closely linked, it is possible that inhibition 
of FAK catalytic activity, may also regulate microtentacle formation in a similar 
manner. All in all, FAK plays an important role in the time-sensitive generation of 
cell-ECM attachment, which may be a mechanism for the differential ECM 
binding that was observed between the BCPAP and 8505Cs in response to FAK 
inhibitor.  
Interestingly, ex vivo imaging of vehicle, pre-treated, and post-treated 
mice revealed that mice pre-treated with PF-562,271 had a higher incidence of 
metastases to the bone compared to either of the other groups. Intriguingly, a 





expression in the regulation of bone resorption, and in vivo studies of other 
cancer types indicate that the rate of bone turnover enhances the occurrence 
and progression of metastasis to the bone (178–181). In addition, bone 
resorption has been linked to enhanced metastatic growth in other tumor types 
including breast and prostate (180,182). Furthermore, other studies have 
suggested that the interaction between bone cells and cancer cells is critical in 
governing colonization of the bone (130). Although more studies are needed, 
these findings point to a potential mechanism mediating an enhanced metastatic 
phenotype, likely through the effect of FAK inhibition on bone cells and bone 
resorption.   
Finally, the scaffolding role of FAK provides binding sites for multiple 
oncogenic tyrosine kinases including EGFR, c-MET, and Src, as well as tumor 
suppressors protein such as p53 and NF-1 (183). Therefore, the FAK scaffold 
provides a pool of potential targets, each of which controls highly specific aspects 
of kinase/signaling pathways. Numerous studies have demonstrated that FAK 
scaffolding is important in the development, maintenance, and dissemination of 
cancer (38,75,122,184). Thus, ongoing studies are currently dedicated to 
identifying specific effector proteins and signaling pathway(s) mediated by FAK 
scaffolding functions, which will ultimately allow us to target key protein-protein 
interactions to inhibit FAK-mediated pro-tumorigenic processes important for 
thyroid cancer establishment and metastasis, and further dissect the role of FAK 





In conclusion, we have shown that inhibition of FAK expression versus 
kinase activity regulates distinct pro-tumorigenic processes, and importantly, that 
FAK expression is critical for the regulation of key thyroid tumorigenic functions, 
including anchorage-independent growth, tumor establishment/progression, and 
systemic tumor formation.  Furthermore, knockdown of FAK was able to inhibit 
growth and tumor establishment in BRAF-mutant thyroid cancer models, 
independent of ERK1/2 signaling, demonstrating that these cells are also 
dependent on FAK signaling for growth and survival, and provides strong 
preclinical rationale for targeting FAK in the clinic.  Finally, given that FAK 
functions in parallel to classical oncogenic signaling pathways in thyroid cancer, 
targeting these pathways in combination with FAK may reveal enhanced 

















RESISTANCE TO SRC TARGETED THERAPY ALTERS BRAF-MUTANT 
TUMOR SECRETOME TO PROMOTE AGGRESSIVE PHENOTYPES 
THROUGH A FAK/SRC SIGNALING AXIS 
 
Introduction 
 Thyroid cancer is the most common endocrine malignancy accounting for 
~4% of all new cancer cases diagnosed in 2016 in the U.S. (3). Although most 
patients will respond favorably to standard-of-care therapy, a small percent of 
patients have a poor prognosis and need more therapy options (185).  The 
majority of PTCs and ATCs harbor alterations in one of the genes involved in the 
signaling of the MAPK pathway; RET/PTC rearrangements are found in 30-40%, 
BRAF mutations in approximately 40-50%, and RAS mutations in about 10% of 
tumors (8,185).  These genetic alterations result in constitutive activation of the 
MAPK pathway, which regulates pro-tumorigenic processes in thyroid cancer 
(8,186). Accordingly, there is great interest in targeting the MAPK pathway for 
therapeutic use, however in contrast to melanoma, the clinical responses of 
thyroid cancer to MAPK pathway inhibition have been less than satisfactory 
(15,187) demonstrating a clear need for unique therapeutic approaches. 
Our lab has previously identified Src as a novel therapeutic target in 
thyroid cancer due to its involvement in many pro-tumorigenic processes 
(141,142). However, Src inhibitors have had limited efficacy in the clinic likely 
due to underlying resistance mechanisms (188,189). In order to more effectively 
target Src, we generated a panel of four thyroid cancer cell lines resistant to the 





reactivation of the MAPK pathway as a conserved mechanism of resistance in 
BRAF- and RAS-mutant cells (140).  Mechanisms of resistance to other MAPK 
pathway inhibitors, including BRAF V600E inhibitors (vemurafenib) and MEK 
inhibitors, have identified similar reactivation of the MAPK pathway (21,190–195). 
Interestingly, the dasatinib resistant state was accompanied by an inhibitor-
induced invasive phenotype, which has been observed in other cancers that 
exhibit intrinsic or acquired resistance to tyrosine kinase inhibitors. This 
reversible, non-genetic change in phenotype, termed “phenotype switching”, 
allows tumor cells to dedifferentiate and adopt a more mesenchymal-like state, 
which can increase the dissemination of resistant tumor cells to distant sites and 
contributes to therapeutic escape (22). Several mechanisms that induce 
phenotype switching in response to therapy have been proposed, including 
activation of the Src/FAK signaling pathway, and combination therapy targeting 
these mechanisms have shown promise in improving drug responses and limiting 
invasion and metastasis (24–26,30,98).  
  FAK is a non-receptor tyrosine kinase involved in mediating many cellular 
and biological processes including cell survival, proliferation, and invasion 
through both kinase and scaffolding abilities (43). Invasion is mediated through 
Src/FAK signaling as external stimuli from either integrins or growth factor 
receptors leads to autophosphorylation of FAK, providing a high affinity SH2 
binding site for Src. Src then phosphorylates additional residues on FAK, 
including residues in the kinase and focal adhesion targeting domains, which are 





downstream effector pathways. Binding of p130Cas to FAK requires intact 
proline residues, Pro712/713, as well as the Src-phosphorylated tyrosine residue 
on FAK, 861 (67,68). Further formation of the Src-FAK-p130Cas-Dock180 
signaling complex results in activation of downstream effectors Rac, JNK, and 
ERK, which in turn promote cell motility and transcriptional regulation of pro-
invasive genes, including expression of MMPs (81). We have previously shown 
that FAK is overexpressed and activated in thyroid cancer cell lines and 
advanced PTC patient samples (141).  
Treatment with targeted therapies, including BRAF, ALK, or EGFR kinase 
inhibitors, have been shown to alter the proteins that are secreted by cancer 
cells, which results in an induced secretome that can stimulate growth, survival, 
and dissemination of cancer cells (143). Many of these secreted proteins have 
been identified to control and regulate cancer cell invasion and metastasis 
(24,196).  Pro-inflammatory cytokines are major contributors of tumor cell 
invasion. Of these, interleukin-1 (IL-1) signaling can stimulate tumor growth and 
invasion through activation of many pathways including protein kinase B, MAPK, 
Stat, and nuclear factor–�B pathways (NF�B), as well as activation of signaling 
proteins Src and FAK (197). Activation of these signaling pathways is required for 
production of MMPs, essential for tumor cell invasion (197,198).  
In the present study, we identified a Src inhibitor-induced invasive 
phenotype that was specific to BRAF-mutant thyroid cancer cells and reliant on 
FAK/p130Cas signaling, which controls c-JUN activity. Combined FAK and Src 





p130Cas using shRNAs phenocopied these results. Chronic Src inhibition altered 
the tumor cell secretome, resulting in the upregulation of IL-1  and MMPs, which 
are mediated by a FAK/Src signaling axis. Blocking IL-1  or inhibiting MMPs both 
significantly reduced invasion, suggesting a role for these proteins in mediating 
the phenotype switch. In addition, an upfront combination of FAK and Src 
inhibition in a panel of thyroid cancer cell lines had synergistic effects on growth 
inhibition. Our results strongly suggest that chronic Src inhibition in BRAF-mutant 
thyroid cancer cells promotes a switch in FAK dependency from scaffolding to 
kinase activity, which could be targeted as an upfront therapy to increase the 
efficacy of single-agent Src targeted therapies in the clinic. 
 
Results 
Cellular Morphology is Altered in BRAF-Mutant Cells Upon Resistance to 
Dasatinib 
 
We previously established a model of chronic Src inhibition in both BRAF- 
and RAS-mutant thyroid cancer cell lines, which allows for the acquisition of 
dasatinib resistant mechanisms, through increasing the concentration of 
dasatinib in culture medium over a period of approximately 9 months until cells 
were maintained in 2µM (control cells were cultured in DMSO alongside) (140). 
As a mechanism of resistance, we have previously shown that dasatinib-
resistance results in reactivation of the MAPK pathway in both BRAF- and RAS-
mutant models, with significant increases in phospho-ERK after resistance is 
acquired. In addition, in the control cells we observe an increase in phospho-ERK 





demonstrated that the RAS-mutant, but not BRAF-mutant, dasatinib resistant 
(DasRes) cells had acquired the c-Src gatekeeper residue, which blocks drug 
binding and allows for continued activity of Src even in the presence of drug 
(140). Genome-wide RNA sequencing has not identified any acquired genetic 
alterations in the BRAF-mutant DasRes cells, suggesting that mechanisms of 
signaling adaptation to promote drug resistance are likely occurring in these 
cells. Due to the reactivation of the MAPK pathway as a mechanism of resistance 
which regulates cell proliferation, we analyzed cell doubling time, but no 
significant changes in proliferation were observed between control and DasRes 
cells (Figure 4.1).  
Interestingly, bright-field images of the DasRes cells revealed changes in cellular 
morphology. Acquired resistance to dasatinib promotes a more fibroblastic, 
spindle-like phenotype in the BRAF-mutant (BCPAP and SW1736) DasRes cells, 
while the RAS-mutant cells (Cal62 and C643) have increased focal adhesion-like 
Figure 4.1: Proliferation is not altered in dasatinib-resistant cell lines. 
Control and DasRes cells for each cell line were plated at identical concentrations 
at Day 1 and then harvest and counted at Days 3, 5, and 7. Doubling time was 






contacts (Figure 4.2A-left). To quantify these changes in cell morphology, the 
aspect ratio was measured and calculated; both BRAF-mutant DasRes cell lines 
were found to have a significantly increased aspect ratio (more elongated 
morphology; p≤0.0001), while no changes were observed between the drug-
sensitive and -resistant RAS-mutant cell lines (Figure 4.2A – right; p=n.s.). 
 
Acquired Resistance to Dasatinib Promotes Migration and Invasion in Models of 
BRAF-Mutant Thyroid Cancer Cell Lines   
 
Due to alterations observed in cellular morphology, we next evaluated 
cellular migration and invasion. We hypothesized that a morphological switch to 
more fibroblast-like cell would promote migration/invasion of the BRAF-mutant 
Figure 4.2: Cellular morphology and motility is altered in dasatinib-
resistant cells. (A) Brightfield images were taken (10x magnification) of control 
and DasRes cells (left) and quantification of aspect ratios was performed using 
ImageJ. Migration (B) and Invasion (C) of control and DasRes cells was 
quantified after 24 hours. DasRes data was normalized to control set to 1. Data 
shown are mean ± SEM of 3 independent experiments performed in duplicate. 






DasRes cells. We performed directional migration assays using Boyden 
chambers, where cells were allowed to migrate towards 10% FBS. The BRAF-
mutant dasatinib-resistant cells were significantly more migratory than their 
control counterparts (1.5-2.0-fold increase; BCPAP: p≤0.0001; SW1736: 
p≤0.001), while resistance in the RAS-mutant cell lines had either no effect or 
resulted in a significantly less migratory phenotype (Figure 4.2B; C643: p≤0.001; 
Cal62: p=n.s.). Next, invasion through Matrigel towards 10% FBS was assessed. 
Invasion of the DasRes cells was significantly increased in the BRAF-mutant cell 
lines (1.5-2.2-fold increase; BCPAP: p≤0.05; SW1736: p≤0.001), and significantly 
decreased in the RAS-mutant cells lines (p≤0.001) compared to their respective 
controls (2.0-3.3-fold decrease) (Figure 4.2C). The results of both the directional 
migration and invasion assays support our hypothesis, that the BRAF-mutant 
DasRes cells have acquired a more motile and invasive phenotype.  
 
Inhibitor-Induced Phenotype Switching is Mediated by Increased FAK and Src 
Signaling 
 
Mechanisms of resistance to kinase inhibitors can occur through 
increased dependence on alternative signaling pathways, and may also rely on 
plastic, reversible traits induced by drug pressure (98,199). Due to the close 
relationship between Src and FAK signaling, as well as the known role for FAK in 
invasion and migration, we hypothesized that increased FAK signaling may be a 
mechanism of resistance to dasatinib, and may be promoting cell motility and 
invasion. To test this, we evaluated invasion of the DasRes cells in the presence 





inhibitors. Interestingly, no effect on invasion was observed with single-agent 
FAK inhibitor, and as expected, the resistant-cells were not affected by dasatinib 
(Figure 4.3A).  However, a significant decrease in invasion was observed in the 
Figure 4.3: Dasatinib-resistant BRAF-mutant cells are rewired to signal 
through FAK. (A) Invasion of DasRes cells after 24 hours in the presence of 
DMSO, 100nM PF271, 2�M dasatinib, or the combination of 100nM PF271 and 
2�M dasatinib was quantified. Results were normalized to DMSO-treated 
control set to 1. Results shown are mean ± SEM of 3 independent experiments 
performed in duplicate. Data analyzed with paired t-test. (B) Western blot 
analysis was performed on cells treated with the indicated concentrations of PF-
562,271 and/or dasatinib for 24 hours. 3 independent experiments were 







BRAF-mutant DasRes cells with combined FAK and Src inhibition (2.2-2.8-fold 
decrease; Figure 4.3A; p≤0.001), suggesting that both FAK and Src kinase 
activity mediate the increased invasive phenotype resulting from chronic 
dasatinib treatment. As predicted, no changes in RAS-mutant DasRes invasion 
were detected (Figure 4.4).  
To better understand the mechanism of combined FAK and Src inhibition 
in the DasRes cells, we performed Western blot analysis. In both the BRAF- and 
RAS-mutant cells lines, treatment with increasing concentrations of the 
FAK/PYK2 inhibitor PF-562,271 alone (0.1-1 �M) showed slight decreases in the 
auto-phosphorylation site of FAK, Y397 (Figure 4.3B). In the both BRAF-mutant 
control and DasRes cell lines, as well as the RAS-mutant control cells, the 
decrease in pY397 was more profound with combined PF-562,271 and dasatinib 
treatment (Figure 4.3B and Figure 4.5). In both of the control cell lines (BCPAP 
and C643), the addition of dasatinib decreases both Y416Src and Y861FAK  
Figure 4.4: Sensitivity to FAK inhibition is limited to BRAF-mutant 
dasatinib resistant cells. Invasion of RAS-mutant Cal62 (left) and C643 (right) 
DasRes cells was quantified after 24 hours in the presence of DMSO control, 
100nM PF-562,271, 2�M dasatinib, or the combination of 100nM PF-562,271 
and 2�M dasatinib. Results were normalized to DMSO-treated control and 






Figure 4.5: Control and BRAF-mutant DasRes respond to combined FAK/Src inhibition through 
regulation of p130Cas and c-JUN phosphorylation. (A) Western blot analysis was performed on cells 
treated with the indicated concentrations of PF-562,271 and/or dasatinib for 24 hours. Signal intensities 
were quantified and levels of phosphorylation of Y397FAK, Y861FAK, Y416Src, ppERK, pS473AKT, 
Y410p130Cas, and S63c-JUN were normalized to levels of total protein before being normalized to the 
appropriate DMSO-treated control. At least 2 independent experiments were performed for each cell line 






phosphorylation, indicating inhibition of Src activity. Likewise, a decrease in 
pY416Src and pY861FAK was observed in the BRAF-mutant DasRes cells 
(Figure 4.3B).  As expected, pY416Src and pY861FAK was not affected in the 
RAS-mutant DasRes cells, because these cells have acquired the gatekeeper 
residue, which allows Src to signal in the presence of dasatinib (Figure 4.3B) 
(140). Of interest, the FAK inhibitor alone slightly decreases pY861 levels in the 
BRAF-mutant cells, but the combination of FAK and Src inhibition decreases 
Y861 phosphorylation more substantially (Figure 4.3B and Figure 4.5). 
Consistent with results from our previous study, Figure 4.3B demonstrates that 
pp42/44-ERK is increased in the DasRes cells compared to the controls(140). As 
such, we observe that in the BRAF-mutant cell lines, a decrease in ppERK levels 
is evident with the combination of FAK and Src inhibition (Figure 4.3B and Figure 
4.5). Of interest, we identified that in the RAS-mutant cells, only the combination 
of FAK and Src inhibition reduces ERK phosphorylation, and no changes are 
observed in the DasRes cells (Figure 4.3B and Figure 4.5). In addition, we 
observed regulation of S473AKT in the BRAF-mutant DasRes cells with the 
single-agent FAK inhibitor, which was more pronounced with the combination of 
FAK and Src inhibition, while only the combination reduces phosphorylation of 
S473AKT in the BRAF-mutant control cells (Figure 4.3B and Figure 4.5). Of note, 
this regulation of S473AKT phosphorylation was also observed in the RAS-
mutant control cells upon treatment with both the FAK and Src inhibitors. These 





and dasatinib, may also regulate the proliferation and survival of the thyroid 
cancer cells through ERK and AKT.  
FAK and Src signaling can promote migration and invasion by activation of 
the key downstream target and adaptor protein, p130Cas (51,200).  Figure 4.3B 
shows that phosphorylation of p130Cas at Y410 in the control cell lines is 
inhibited by dasatinib treatment in both BRAF- and RAS-mutant control cells. 
Interestingly, phosphorylation of p130Cas is not inhibited with single-agent FAK 
inhibitor treatment, and phosphorylation levels in the BRAF-mutant control cells 
actually increase, potentially as a mechanism of compensation (Figure 4.3B and 
Figure 4.5). Interestingly, the combination of FAK and Src inhibition blocked this 
paradoxical increase, and further decreased the phosphorylation of p130Cas in 
both the BRAF- and RAS-mutant control cells (Figure 4.3B and Figure 4.5). 
Together, these results indicate that p130Cas is phosphorylated predominantly 
by Src in our thyroid cancer cell lines, with some potential compensatory input 
from FAK kinase activity. In the DasRes cells, a decrease in pY410-p130Cas 
levels was detected with FAK inhibitor treatment alone, and with single-agent 
dasatinib (Figure 4.3B and Figure 4.5). The combination of FAK and Src 
inhibition however dramatically decreases phosphorylation of Y410-p130Cas in 
the BRAF-mutant DasRes cells, and no consistent change is observed in the 
RAS-mutant cells (Figure 4.3B and Figure 4.5). In addition, p130Cas expression 
is required for efficient invasion of the BRAF-mutant DasRes cells but not their 





that a signaling adaptation through FAK-Src-p130Cas has occurred which 
promotes an invasive phenotype in response to chronic dasatinib treatment.  
The ability of p130Cas to promote invasion and migration requires a 
signaling cascade which can result in the ultimate activation of the transcription 
factor c-JUN, a member of the AP-1 transcription factor complex (201). To 
assess the potential activity of c-JUN, we probed for phosphorylation of c-JUN at 
S63 which is phosphorylated by JNK and mediates c-JUN activity (202,203).  
In the RAS-mutant cell lines, the FAK inhibitor alone has no effect on c-JUN 
phosphorylation. However, in the BRAF- mutant cell lines, single-agent FAK 
inhibitor slightly decreases phosphorylation of c-JUN (Figure 4.3B and Figure 
4.5). In both the control cells, dasatinib alone has no effect, but the combination 
of FAK and Src inhibition depletes total c-JUN levels, which also results in 
decreased phosphorylation (Figure 4.3B). Consistent with the observed p130Cas 
Figure 4.6: P130Cas mediates invasion of BRAF-mutant DasRes cells.  
BCPAP control and DasRes cells were stably transfected with a scramble 
control shRNA (SHC016) or an shRNA targeting p130Cas (shP130Cas). (A) 
Invasion was performed and data from each cell line was normalized to SHC016 
expressing cells. Results shown are mean ± SEM of 3 independent experiments 
performed in duplicate. (B) Western blot analysis was performed on 2 






signaling in the DasRes cells, pS63 c-JUN levels are decreased in response to 
combined dasatinib and PF-562,271 treatment in the BRAF-mutant DasRes cells 
(Figure 4.3B and Figure 4.5). Of interest, in the BRAF-mutant cells, an increase 
in total c-JUN levels were observed, which correlated with resistance, as was 
previously identified by Ramsdale et al in melanoma (Figure 4.7) (27). 
Phosphorylation of c-JUN in our model is mediated, at least in part, through 
upstream p130Cas signaling, as knockdown of p130Cas in the BRAF-mutant 
cells results in decreased pS63 levels (Figure 4.6B). Taken together, our 
signaling and invasion data suggests that upon resistance to dasatinib, BRAF-
mutant thyroid cancer cells adapt to signal through a FAK-Src-p130Cas axis, 
which regulates c-JUN phosphorylation, resulting in an inhibitor-induced invasive 
phenotype.  
 
Figure 4.7: c-JUN expression is increased in BRAF-mutant DasRes. 
Western blot analysis of at least 2 independent experiments from each BRAF-
mutant cell lines (BCPAP and SW1736) was performed. The signal intensities 
across cell lines were averaged and total c-JUN levels were normalized to α-
tubulin levels before being normalized to the levels of the control cell lines 






Chronic Src Inhibition with Dasatinib Alters the Secretome of BRAF-Mutant 
Thyroid Cancer Cell Lines. 
 
Many target genes of the AP-1 transcription factor complex, of which c-
JUN is a member, are genes that encode pro-inflammatory and pro-invasive 
proteins, many of which are a part of the cancer secretome (204,205). We 
therefore we analyzed RNA-sequencing data previously obtained from the 
control and DasRes cells (140) and subsequently performed transcriptional 
secretome analysis, where a list of known and predicted secreted proteins from 
the Secreted Protein Database (145) (http://spd.cbi.pku.edu.cn/) was extracted 
from our RNA-sequencing data of transcripts that were expressed greater than 
one. Comparing the control cells to the DasRes cells, more than 320 secretome 
genes were upregulated greater than two-fold in the BRAF-mutant cells, while 
the RAS-mutant cells had only 62 upregulated genes (Figure 4.8A).  To better 
understand the functional applications of these gene expression changes, 
Figure 4.8: BRAF-mutant secretome is altered upon acquired resistance 
to dasatinib. (A) The number of genes involved in the tumor secretome that 
were upregulated greater than 2-fold in the mutant-specific DasRes cells is 
displayed. (B) DAVID (NIH?) was used to apply functional annotation to the list 
of genes upregulated in the DasRes BRAF-mutant cells. The top 6 clusters were 






enrichment analysis was performed using DAVID on the genes upregulated in 
the BRAF-mutant DasRes cells by including both gene ontology (GO) terms and 
KEGG pathways (206). Functional annotation clustering identified 21 clusters, 
with the highest enrichment scores relating to protein kinase activity, 
transcriptional regulation, and metalloprotease activity (Figure 4.8B). These 
results imply that invasion of the BRAF-mutant DasRes cells may be promoted in 
part through altered kinase activity controlling transcription and secretion of pro-
invasive factors, such as MMPs.  
To first test whether secreted factors promote invasion, conditioned media 
was collected from both the BRAF- and RAS-mutant control and DasRes cells, 
and invasion assays were performed on the control cells, in the presence of 
conditioned media from either control or DasRes cells. In the case of the BRAF-
mutant cells (BCPAP and SW1736), conditioned media from control cells had no 
effect on invasion compared to a DMSO-treated control media with 1% FBS, 
however conditioned media from DasRes cells significantly increased invasion of 
control cells (1.2-3.0-fold increase; Figure 4.9A; BCPAP: p≤0.001; SW1736: 
p≤0.01)). As expected, conditioned media from RAS-mutant DasRes cells had no 
effect on invasion (Figure 4.10A). In addition, BRAF-mutant DasRes conditioned 
media was able to induce invasion of RAS-mutant control cells (Figure 4.10C; 
~2.5-fold increase), suggesting that autocrine signaling can occur in the absence 
of any BRAF-specific cellular reprogramming. Interestingly, conditioned media 





in the chamber with the cells (Figure 4.10B), suggesting that the secreted 
factor(s) mediating invasion requires direct contact with cells.  
To identify the key secreted factor(s) that mediate invasion, cytokine 
arrays were performed using conditioned media from Cal62 and BCPAP control 
and DasRes cells (Figure 4.9B). After normalization for background signals, the 
signals from DasRes conditioned media were normalized to conditioned media 
from the controls cells. After excluding targets that were also increased in RAS-
Figure 4.9: Conditioned media from BRAF-mutant dasatinib-resistant cells 
promotes invasion. Conditioned media (CM) was collected from BCPAP (Left) 
or SW1736 (Right) control and DasRes cells. (A) Invasion assays of control 
cells were performed in the presence of 1% FBS control, Control CM, or DasRes 
CM. Results shown are mean ± SEM of 3 independent experiments performed 
in duplicate. Data was analyzed by paired t-test. (B) Conditioned media from 
BCPAP and Cal62 control and DasRes cells was applied to human cytokine 
arrays. Quantification of each array was performed and DasRes CM signals 
were normalized to signals from control CM and displayed as intensity ratio. 






mutant DasRes conditioned media (Figure 4.11A), the main candidates likely  
capable of inducing invasion were ENA-78 or CXCL5, interleukin-1- alpha (IL-1) 
and -beta (IL-1 ) (Figure 4.9B).  
 
IL-1  Signaling Promotes Invasion of BRAF-Mutant Dasatinib-Resistant Cells 
Through FAK/Src Signaling 
 
IL-1 and  are well-known pro-inflammatory cytokines and CXCL5 is an 
pro-angiogenic and –inflammatory chemokine; all 3 of which have been 
Figure 4.10: Only BRAF-mutant dasatinib-resistant conditioned media 
promotes invasion. (A) Conditioned media (CM) from RAS-mutant Cal62 
control and DasRes cells was collected. Invasion of control Cal62 cells was 
performed in the presence of 1% FBS as a control. CM from control cells, or CM 
from DasRes cells. Results shown are mean ± SD of 2 independent experiments 
performed in duplicate and normalized to 1%FBS control set to 1. (B) Invasion 
of BCPAP control cells was performed using CM from control or CM from 
DasRes cells as a chemoattractant (placed below the invasion chamber). 
Quantification was performed and data normalized to CON CM set to 1. Results 
shown are mean ± SEM of 2 independent experiments performed in duplicate. 
(C) Invasion of Cal62 (RAS-mutant) control cells was performed in the presence 
of BCPAP (BRAF-mutant) control CM or DasRes CM. Quantification was 
performed and data was normalized to CM from control cells, set to 1. Results 






demonstrated to mediate tumorigenesis and cancer progression (197,207–209). 
To further narrow down the potential target mediating invasion, we cross 
referenced our RNA-sequencing data which showed an increase in IL-1  mRNA 
transcripts in the BRAF-mutants only (4.4 – 16.4-fold), while only a small change 
in IL-1 was observed (1.2-fold).  Additionally, the receptor for CXCL5, CXCR2, 
was not expressed in any of our cell lines (CXCR2 ≤ 0.013 FPKM). Because of 
the elevated expression IL-1  in both the cytokine array and RNA-sequencing 
data, and its specificity to BRAF-mutant cells, we asked whether IL-1  blockade 
would attenuate invasion in the BRAF-mutant DasRes cells. BCPAP (BRAF-
mutant) control and DasRes cells were pretreated with a neutralizing IL-1  
antibody for 24 hours prior to plating in invasion chambers with the antibody 
present. As shown in figure 4.12A, IL-1  blockade has no effect on invasion of 
the control cells, however invasion was reduced in DasRes cells treated for 48 
hours with a neutralizing IL-1  antibody (~1.6-fold decrease) (Figure 4.12A; 
Figure 4.11: Secretome regulation in RAS-mutant dasatinib-resistant cells. 
(A) Cytokine arrays were performed using Cal62 control and DasRes 
conditioned media. Quantification of the arrays was performed and DasRes CM 
signals were normalized to signals from control CM and displayed as intensity 
ratio. Quantification for Cal62 DasRes CM is displayed as intensity ratio. (B) 






p≤0.001). Because IL-1  was identified as a secreted factor in the conditioned 
media from drug-resistant BRAF-mutant cells, we preformed invasion assays 
using conditioned media in the presence or absence of IL-1  blockade. 
Consistently, invasion of BCPAP control cells was unaffected by conditioned 
media from control cells, with or without anti-IL-1  treatment.  The invasive 
phenotype promoted by conditioned media from drug-resistant BRAF-mutant  
Figure 4.12: IL-1  promotes invasion through activating FAK and Src. (A) 
Invasion assays of BCPAP control and DasRes cells were performed in the 
presence of absence of 0.1ug/mL of IL-1  neutralizing antibody. Quantification 
was performed and data from each cell lines was normalized to its respective 
DMSO-treated control. Results shown are mean ± SEM of 3 independent 
experiments performed in duplicate. (B) Invasion of BCPAP control cells was 
performed in the presence of either BCPAP Control conditioned media or 
DasRes conditioned media, treated with either DMSO or anti-IL-1 . 
Quantification was performed and data was normalized to the appropriate 
conditioned media treated with DMSO. Results shown are mean ± SEM of 3 
independent experiments performed in duplicate. (C)  Western blot analysis was 
performed on BCPAP control and DasRes cells treated with the indicated 
concentration of anti-IL-1 . 2 independent experiments were performed and a 






cells was abrogated with anti-IL-1  treatment (~2.5-fold decrease; p≤0.01; Figure 
4.12B).  These results suggest that chronic treatment with dasatinib promotes 
cellular signaling that induces secretion of pro-inflammatory cytokine IL-1 , which 
signals in an autocrine manner to promote a more invasive phenotype.    
Localization of IL-1 receptors to focal adhesion is critical for IL-1 signal 
transduction as phosphorylation and activation of FAK is required (210). IL-1  
has been shown to increase FAK and Src phosphorylation which promotes 
invasion of breast cancer cells (198).  To determine if a similar mechanism is 
occurring in our model, we performed Western blot analysis on BCPAP (BRAF-
mutant) control and DasRes cells treated with the neutralizing IL-1  antibody for 
48 hours. Consistent with previous reports, phosphorylation of FAK at Y397 was 
inhibited in both the control and DasRes cells with IL-1  blockade (1.6- and 3.2-
fold inhibition, respectively).  Interestingly, a decrease in pY416Src was only 
observed in the DasRes cells and correlated with decreased phosphorylation of 
Y861FAK (Figure 4.12C; 1.9-fold inhibition). In the control cells, the decrease in 
FAK phosphorylation correlated with decreased phospho-p130Cas levels after 
IL-1  blockade, resulting in a 1.7-fold inhibition, but no effect on phosphorylation 
of c-JUN was observed. In the DasRes cells, a reduction in FAK and Src activity 
correlated with reduced phosphorylation of both p130Cas and c-JUN when 
treated with anti-IL-1  (1.8- and 3.9-fold inhibition, respectively; Figure 4.12C). 
Taken together with the invasion data (Figure 4.12A and 4.12B), these results 
suggest that IL-1  signals in an autocrine fashion to promote FAK and Src 





notion that inhibition of the entire signaling module may be necessary to 
modulate functional effects.  
 
MMP Transcription and Activity are Increased in BRAF-Mutant Dasatinib-
Resistant Cells Through FAK/Src Activity 
 
Several studies have demonstrated that inhibitor-induced invasion can 
occur, in part, through regulation of MMPs (24,26). FAK activity has been shown 
to regulate MMP expression (96,198,211,212) and many MMPs are target genes 
of c-JUN and the AP-1 complex (27,205). Therefore, using qRT-PCR, we 
analyzed the transcript levels of MMP-2 and MMP-9. At baseline, we observed 
increases in the transcripts of both MMP-2 and -9 in the BCPAP (BRAF-mutant) 
DasRes cells compared to controls (Figure 4.13A; MMP-2: 8-fold; MMP-9: 37-
fold). No changes in MMP expression were observed in the RAS-mutant cells 
(Figure 4.11B). An increase in the transcript level of IL-1  was also observed in 
the BRAF-mutant DasRes cells compared to control (36-fold increase), 
suggesting that IL-1  expression in these cells is, at least in part, under 
transcriptional regulation (Figure 4.13A).  To demonstrate that the increase in 
MMP transcripts levels correlates to functional protein that contributes to the 
invasive phenotype observed, invasion assays were performed using conditioned 
media from BRAF-mutant DasRes cells treated with either the broad spectrum 
MMP inhibitor, GM6001, or the selective MMP-2 and -9 inhibitor, SB3CT. Figure 
4.13B demonstrates that MMP inhibition attenuates the increased invasion 
resulting from treatment with conditioned media from DasRes cells (~2.4-6.8-fold 





resistant cells.  The activity of specific MMPs in the conditioned media was 
assessed using zymography assays. As expected, active MMP expression in the 
RAS-mutant conditioned media was minimal and decreased with drug-resistance 
Figure 4.13: Transcription and activity of MMP-2 and MMP-9 are 
increased in BRAF-mutant drug-resistant cells. (A) Transcript expression 
was analysis by qRT-PCR in the BCPAP control and DasRes cells. (B) 
Invasion of BCPAP control cells was performed in the presence of control 
conditioned media (CM), DasRes CM, or DasRes CM treated with ? GM6001 
or ? SB3CT.  Quantification was performed and data normalized to control CM 
set to 1. Results shown are mean ± SD of 2 independent experiments 
performed in duplicate. (C) MMP activity was assessed by zymography assay. 
(Left) Conditioned media as indicated was loaded onto gelatin-containing gels 
and protease activity was demonstrated as white bands on back background. 
(Right) Gelatin-degradation in the indicated lanes was quantified using ImageJ. 
(D and E) BCPAP control or DasRes cells were treated with the either DMSO, 
1�M PF-562,261, dasatinib (30nM for controls, 2�M for DasRes), or the 
combination of PF-562,271 and dasatinib as appropriate. Transcripts levels of 






(~3-fold; Figure 4.13C – lanes 1 and 2). Interestingly, only MMP-9 was detected 
in the RAS-mutant conditioned media, while in the BRAF-mutant conditioned 
media, both MMP-2 and -9 were detected. Consistent with the observed increase 
in invasion, conditioned media from the BRAF-mutant DasRes cells contained 
higher MMP-2 and MMP-9 activity compared to conditioned media from the 
control cells (2.9- and 2.0–fold increase, respectively) (Figure 4.13C – lanes 3 
and 4).  Treatment with GM6001 (lane 5) decreased MMP-2 activity only slightly, 
but had a greater effect on MMP-9 activity compared to untreated DasRes 
conditioned media (1.2- vs 1.4-fold decrease). Treatment with SB3CT (lane 6) 
showed a similar effect to GM6001, where MMP-2 activity was decreased 
minimally, however the reduction in MMP-9 activity was substantial, reducing 
MMP-9 activity levels back to that of the control conditioned media (1.4- and 9.8-
fold decrease, respectively; Figure 4.13C).  
Of interest, IL-1  has been shown to mediate MMP-9 production through 
regulation of FAK and Src activity (198). To determine the role of FAK and Src 
activity in mediating MMP-9 transcription, BCPAP (BRAF-mutant) control and 
DasRes cells were treated with the FAK inhibitor PF562,271, dasatinib, or the 
combination for 24 hours and then probed for MMP-9 transcript expression. In 
the DasRes cells, treatment with either single-agent inhibitor reduced MMP-9 
transcript levels compared to the DMSO-treated control. As predicted, the 
greatest decrease in MMP-9 transcript was observed with combined inhibition of 





and Src signaling can regulate MMP-9 expression through transcriptional 
regulation.  
 
FAK and Src Activity Regulates IL-1  Transcription 
Based on previously known connections between FAK/Src and IL-1  
expression (198) as well as our data demonstrating transcriptional regulation of 
IL-1  in the DasRes cells (Figure 5A), we asked whether inhibition of FAK, Src, 
or the combination could regulate IL-1  transcription. Indeed, in the DasRes 
cells, the inhibition of FAK alone, as well as the combination of FAK and Src 
inhibition, reduced IL-1  transcript levels (Figure 4.13E). Interestingly, IL-1  
transcripts were higher in the DasRes cell compared to controls, demonstrating a 
potential correlation between acquired resistance and IL-1  levels. These results 
suggest that IL-1  transcription may be controlled by FAK/Src activity and, taken 
together with our anti-IL1  Western data, that IL- 1  is both downstream and 
upstream of FAK and Src signaling.  
 
Combined FAK and Src Inhibition Synergistically Decreases Growth in Thyroid 
Cancer Cells 
 
FAK/Src signaling plays a key role not only in cell migration and invasion, 
but also in many other pro-tumorigenic processes (32).  Indeed, we observed 
regulation of several components of proliferation and survival pathways, as 
phosphorylation of ERK and AKT were decreased with FAK and Src inhibition 
(Figure 4.3B and Figure 4.5). Therefore, SRB growth assays were employed to 
evaluate the sensitivity of the DasRes cells to FAK inhibition. The IC50 values of 
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Figure 4.14: BRAF-mutant dasatinib-resistant cells are sensitive to FAK 
inhibitors in the presence of dasatinib. SRB assays were performed to 
assess cell growth of BRAF-mutant (left) and RAS-mutant (right) control and 
DasRes cells. Cells were treated with the indicated concentration of (A) PF-
562,271 or (B) PF-573,228. The DasRes cells were maintained in the presence 
of 2�M dasatinib. Results shown are mean ± SEM of 3 independent experiments 







As we have previously shown, DasRes cells are resistant to dasatinib 
concentrations greater than 5µM, and are continually maintained in 2µM 
dasatinib with no effects on proliferation (140).  Alone, DasRes cells are not 
sensitive to FAK inhibition, as they exhibit IC50 values similar to that of their 
corresponding controls, which is consistent with our previous data on parental 
cells (Figure 3.2) (213). However, maintaining BRAF-mutant DasRes cells in 2µM 
dasatinib and treating with increasing concentrations of PF-562,271 increased 
the sensitivity of these cells to FAK inhibition, compared to their controls (~3-10-
fold increase in sensitivity) (Figure 4.14A). There was no change in sensitivity in 
the RAS-mutant cells lines (Figure 4.14A). This increase in sensitivity was 
observed with another FAK-specific inhibitor, PF-228,573 (Figure 4.14B). As 
previously mentioned, the RAS-mutant DasRes cells have acquired a c-Src 
gatekeeper residue, resulting in constitutive Src activity even in the presence of 
dasatinib (140).  
Upfront combinations are becoming increasingly accepted due to their 
potential to combat mechanisms of acquired resistance. As we observed in figure 
4.3B, control cell lines were sensitive to combined FAK and Src inhibition, with 
corresponding decreases in ERK and AKT signaling. To test the effects of 
combined FAK and Src inhibition on cell growth we exposed a panel of thyroid 
cancer cell lines to increasing concentrations of dasatinib, in combination with 
either 100nM or 1µM concentrations of the FAK/PYK2 inhibitor, PF-562,271. 
Using SRB assays, BLISS additivity scores were generated to determine what 





Inhibition over bliss additive scores demonstrate concentrations at which the 
combination of drugs synergistically reduce growth. Representative graphs of 
thyroid cancer cell lines are shown in Figure 4.15A.  IC50 values were also 
calculated from the SRB assays, and demonstrate increased sensitivity to 
dasatinib when cells are treated with either concentration of PF-562,271 (Figure 
4.15B). 
 
Figure 4.15: Combined FAK and Src inhibition synergistically decreases 
growth in a panel of thyroid cancer cells. (A) A panel of thyroid cancer cell 
lines were treated with increasing concentrations of dasatinib and the indicated 
concentrations of PF-562,271 and analyzed by 3 independent SRB assays 
performed in triplicate. Bliss additivity scores were calculated. Results shown 
are inhibition over bliss additivity scores to demonstrate increased combination 
inhibition over additivity. Graphs of representative cell lines are shown. (B) IC50 
values for dasatinib and the combination of dasatinib and the indicated 
concentrations of PF-562,271 were calculated and are displayed in the table 
and the graph on the right. Results shown are mean IC50 values ± SD. Fold 
changes and p-values were calculated using Students t-test and are noted 






Taken together, these results suggest combined FAK and Src inhibition 
synergistically reduces thyroid cancer cell growth, and that an upfront 
combination of a FAK and Src inhibitor may be beneficial in the clinic.  
Sensitivity to FAK inhibitor is dependent on Src activity, as stable expression of 
the c-Src drug-resistant residue in the BRAF-mutant DasRes cells confers 
resistance to FAK inhibition (Figure 4.16). Together these results suggest that 
combined inhibition of both FAK and Src are necessary to reduce cell growth in 
drug-resistant cells.  
 
Discussion 
There are few effective therapy options for patients with advanced thyroid 
cancer, and while the majority of these tumors harbor mutations resulting in 
constitutive activation of the MAPK pathway, intrinsic resistance to MAPK 
inhibition is well established (8,15,185,187). We have focused on targeting c-Src 
as an alternative, clinically relevant pathway in thyroid cancer, however, recent 
studies have shown the effectiveness of Src inhibitors in other tumors is 
Figure 4.16: c-Src mediates resistance to FAK inhibition. BCPAP DasRes 
cells were stably transfected with a c-Src gatekeeper expression vector and 






inadequate (188,189). The limited efficacy of many targeted therapies has been 
attributed to adaptation of intracellular signaling, and recent studies indicate the 
regulation of cytokines that support phenotype switching and cancer cell survival 
may be an important mechanism (20,24,27,199,214–216). In this vein, our 
current study demonstrates that BRAF-mutant thyroid cancer cells adapt to 
chronic Src inhibition by signaling through FAK/Src/p130Cas to regulate c-JUN 
Figure 4.17: Proposed mechanism for response to combined FAK and Src 
inhibition in thyroid cancer cells. Combined FAK and Src inhibition has the 
potential to inhibit both the proliferative and invasive populations of cancer cells. 
Activation of the PI3K/AKT and MAPK pathway mediates cell proliferation and 
survival. The MAPK pathway can also promote transcription of MMPs, such 
MMP-2 and -9, to mediate invasion. Combined FAK and Src inhibitor treatment 
inhibits the MAPK and PI3K pathway through decreased phosphorylation of 
ERK and AKT, respectively. FAK/Src signaling contributes to invasion through 
a FAK/Src/p130Cas signaling module which results in increased c-Jun 
expression and phosphorylation, and increased IL-1  and MMP-9 expression. 
IL-1  then potentiates FAK/Src/p130Cas signaling through an autocrine 
signaling loop. Combined FAK and Src inhibition inhibits FAK and p130Cas 
phosphorylation and decreases c-JUN, IL-1 , and MMP-9 expression. Adapted 






activity, and alter the tumor secretome, resulting in upregulated MMP-2, MMP-9, 
and IL-1 , which signals in an autocrine manner to promote a FAK/Src signaling 
(Figure 4.17).  Together with our previous study, which established scaffolding as 
the primary FAK function to regulate pro-tumorigenic processes in thyroid cancer 
(213), we demonstrate that a switch in cell dependency from FAK adaptor 
functions to FAK kinase activity occurs in response to chronic Src inhibition 
(Figure 4.18). Targeting the FAK/Src pathway overcomes resistance in BRAF-
mutant cells, and synergistically decreases cell growth and survival in a panel of 
thyroid cancer cell lines, independent of mutational status suggesting that an 
upfront combination may be therapeutically beneficial (Figure 4.17).  
In this chapter, I show that chronic Src inhibition induces a migratory and 
invasive phenotype in BRAF-mutant thyroid cancer cells. More specifically, 
chronic treatment with dasatinib alters cellular morphology of cells in a mutant-
specific fashion, where BRAF-mutant, but not RAS-mutant cells, became more 
Figure 4.18: FAK functions and Src activity in thyroid cancer cell lines. At 
baseline conditions in thyroid cancer cell lines, FAK scaffolding functions are 
primarily responsible for regulating pro-tumorigeneic processes, while FAK 
kinase activity is dispensable. Upon Src inhibition, a switch occurs in the cell 
dependency from FAK scaffold to FAK kinase functions; cell growth, survival, 






elongated, more migratory, and more invasive (Figure 4.2). Several studies have 
demonstrated that therapeutic adaptation leads to an a change in morphology, 
such as epithelial-to-mesenchymal (EMT) transition, which can be associated 
with increased tumor invasion and metastasis (24–30). In a model of EGFR-
mutated non-small cell lung cancer, the FAK/Src signaling pathway was identified 
as a novel mediator of drug-induced EMT and drug-resistance (28). In addition, 
FAK was causally associated with dasatinib resistance, and combined FAK and 
Src inhibition led to synergistic inhibition of pY397FAK, and enhanced antitumor 
activity both in vitro and in vivo (217,218).  Likewise, we identified FAK/Src 
signaling as a key driver of resistance and a more invasive phenotype in 
response to chronic Src inhibition in thyroid cancer (Figure 4.3).  
We uncovered a central role for FAK/Src signaling and p130Cas-regulated 
c-JUN activity in mediating the BRAF-mutant tumor secretome by promoting 
upregulation of AP-1 target genes IL-1 , MMP-2 and MMP-9. This mechanism 
contributes to phenotype switching and cell survival in response to Src inhibitor 
resistance. Our findings mirror other studies that demonstrate cellular signaling 
adaptation, not genetic alterations, can mediate inhibitor resistance 
(20,27,216,219,220). In a study of melanoma, c-JUN has been shown to promote 
phenotype switching and cell survival associated with BRAF-MEK-ERK pathway 
inhibitor resistance, both intrinsic and acquired, through downregulation of a 
negative regulator of the MAPK pathway, SPROUTY4, after ERK inhibition 
(27,216). However, our BRAF-mutant dasatinib-resistant cells show a 2-fold 





17.04), and increases in ppERK levels upon dasatinib treatment in both resistant 
and drug-sensitive cells. These inconsistencies can be explained however, as 
off-target effects of dasatinib promote the formation of RAF dimers and continued 
ERK pathway activation (140). As a result, SPRY gene expression is induced in 
an attempt to create a negative feeback loop, but acts upstream of the activated 
RAF dimers, by impeding RAS signaling via disruption of GRB2 and SOS 
binding, and therefore, has no effect on ERK phosphorylation. Regarding c-JUN, 
in our model, we observe changes in expression and activity upon dasatinib 
treatment, suggesting that c-JUN regulation and its downstream effects (i.e 
phenotype switching) may be mediated through another signaling pathway, 
namely Src-FAK-p130Cas. Interestingly, total levels of c-JUN have been shown 
to correlate with resistance, and indeed, we observed a similar biomarker of 
response (Figure 4.5) (27,31,216,221).  
Of further interest, previous studies have demonstrated that targeting c-
JUN upregulation was effective against adaptive resistance mechanisms. In our 
study, we clearly show that combined FAK and Src inhibition depletes total c-
JUN levels. Future studies will test the role of c-JUN in mediating resistance and 
adaptive plasticity through knockdown and rescue approaches.  If c-JUN is a 
mediator of these responses, combined FAK and Src inhibition would be an 
effective upfront combination therapy against signaling adaptation in response to 
Src inhibition in thyroid cancer, and this therapeutic approach may also be a 
useful therapy option against other inhibitors (i.e BRAF/MEK inhibitors) and 





In addition, studies demonstrate similar findings to our results where 
inhibitor resistance leads to an increased invasive phenotype through increased 
MMP expression and activity (24,26). The identification of upregulated IL-1 , and 
alterations in the tumor secretome has been recognized by several recent 
studies (143,199,214). While the specific role of IL-1  in mediating resistance to 
Src inhibition in our model requires additional experiments, IL-1  inhibition in vitro 
and in vivo can be achieved using anakinra, an FDA-approved recombinant IL-1 
receptor type I and II antagonist for use in patients with rheumatoid arthritis 
(222).  Our work and others suggests that therapy-induced secretome alterations 
occur through transcriptional reprogramming, which is regulated by adaptations 
of specific intracellular signaling networks. Of particular concern, is that this 
responsive tumor secretome is changed by targeted therapies, which can 
paradoxically promote cancer cell invasion and survival (24,143,199,214).  
A major implication of our study is that targeting the Src pathway alone, 
while more effective in vitro than targeting the MAPK pathway in thyroid cancer, 
can promote adaptation of initially responsive cancer cells, selecting for cells with 
reduced proliferative potential, and an increased survival advantage with a 
potentially superior ability to metastasize. In our model, consistent with other 
models of signaling adaptation in response to therapy, drug withdrawal restores 
responsiveness to single-agent therapy (140), and suggests that intermittent 
dosing schedule may result in longer-term drug responses (25,28,220). Together, 
these studies clearly provide rationale that the effects from continual single-agent 





survive treatment, through increased fitness and/or increased metastatic 
potential. Solely targeting the kinase activity of FAK is unlikely to completely 
reverse the invasive phenotype driven through the FAK/Src signaling axis in 
resistant thyroid cancer cells. Thus, we believe that rational and effective 
combination therapy may influence efficacy of Src targeted therapies and that 
targeting both FAK and Src should inhibit pathways mediated through each 
kinase, as well as compensatory pathway regulation, thereby limiting invasion as 
well as exhibiting decreases in tumor growth. In fact, we observe synergistic 
inhibition of growth in a panel of thyroid cancer cell lines with combined PF-
562,271 and dasatinib, consistent with decreases in ppERK and AKT signaling 
pathways. Therefore, co-targeting FAK and Src could be an excellent strategy to 
increase Src and FAK inhibitor responses in patients, and would provide a 
therapeutic advantage by potentially targeting both the proliferative and invasive 















DISCUSSION AND FUTURE DIRECTIONS 
 
Previous research has answered many questions about FAK signaling, 
binding partners, activation, and the role that FAK plays in pro-tumorigenic 
processes. Along with important answers however, comes more scientific 
questions. The main question that remains unanswered is which tumors will 
respond to inhibition of which FAK function? The answer to this question is 
required before any type of FAK-directed therapy can be effectively used in the 
clinic. Much more research lies ahead to fully understand this question, and the 
answer will help to more effectively predict the subset of patients that will 
respond to therapy.  
 
Therapeutic Targeting of FAK Scaffolding Functions in Cancer 
 
As our understanding of FAK has evolved, it is clear that FAK 
scaffolding/adaptor functions, independent from the kinase activity, play an 
important and critical role in the initiation, progression, and maintenance of 
disease. Of note, our current use of FAK as a therapeutic target in cancer largely 
ignores this fact. We and other have shown that FAK kinase inhibitors can be 
ineffective, and may also promote metastasis under certain conditions.  
Importantly, we have shown that many pro-tumor activities are mediated by the 
scaffolding functions of FAK. While recent advances in understanding the 
importance of the FAK scaffold have been abundant, we still lack complete 





key protein-protein interactions have not been extensively identified. However, 
targeting the FAK scaffold remains a promising endeavor and, as I see it, can 
occur in two ways.  
First, the specific protein-protein interactions that mediate pro-tumorigenic 
processes need to be identified. This can be achieved by performing rescue 
experiments with genetically altered binding sites on FAK which would identify a 
functional role for FAK binding partners known to bind at those sites. Currently 
unknown binding partners could be identified through pull-down and mass 
spectrometry experiments, such as the proximity-dependent biotin identification 
(BioID) method (223). Using this technique, FAK and the binding site mutants 
would be fused to a promiscuous biotin ligase and each expressed in cells. The 
addition of biotin into the system leads to efficient biotinylation of endogenous 
proteins that are adjacent to and interacting with FAK or the mutant constructs, 
which are captured by streptavidin pull-down, and identified by mass 
spectrometry. Identification of these binding partners, and ultimately, pathways 
that are activated downstream (and upstream) through FAK scaffold functions, 
can provide a therapeutic target for inhibition with already available therapies, 
such as inhibition of JNK, AKT, and ERK1/2.  
The second approach to target FAK scaffolding functions is to directly 
target the protein-protein interactions of interest. However, a valid consideration 
for this approach relies on the ability to successfully develop therapeutics that are 
capable of disrupting PPIs and inhibiting downstream signaling. While this 





rapidly expanding and is predicted to lead to a paradigm shift, where targeting 
the once “undruggable” is now a feasible and achievable method of therapeutic 
intervention. As previously discussed, several PPI inhibitors for FAK interactions 
have been developed, and are currently being used successfully in pre-clinical 
studies. A recent study using the FAK scaffold inhibitor Y15 in thyroid cancer 
demonstrated decreased cell viability and clonogenecity, and increased cell 
detachment and necrosis. These biological effects correlated with changes in 
gene signatures relating to cell cycle, apoptosis, and transcription. Further, this 
study demonstrated synergy in cell viability with Y15 and several multi-kinase 
inhibitors, including sorafenib and sunitinib, in the resistant PTC cell line K1 
(224).  While the Schweppe lab has yet to extensively test this compound, a 
substantial decrease in cell viability in the BCPAP cells was observed (~60% 
reduction with 1�M treatment), providing further evidence that targeting the FAK 
scaffold may be a beneficial therapeutic target. As most our thyroid cancer cell 
lines are reliant on FAK scaffolding functions, testing the effects of Y15, and 
other available PPI inhibitors, in pro-tumorigenic processes would be of great 
interest.  Given these results in thyroid and the effects observed in other cancers, 
further investigation into the efficacy of PPI inhibitors is deserved, both as single-
agents and as part of a rationale combination strategy.  
 
FAK Kinase Activity as a Target for Therapy in Cancer 
My data presented in Chapter III indicates that inhibition of FAK activity 
can exhibit anti-tumor effects, but under certain treatment conditions may also 





may paradoxically increase tumor and metastasis formation (172). As such, the 
exact dose and regiment of a FAK inhibitor approach as a cancer therapy 
requires further investigation. Further testing is certainly warranted, but given the 
complexity of FAK signaling and function, the progress of FAK-directed therapy 
development and application will require a multidisciplinary approach that 
combines cancer cell biology, animal and 3D models of cancer, and the 
development of suitable biomarkers of response.  
Another question to ask is whether FAK inhibitors can be used alone as a 
single-agent therapy, or whether rationale combination therapy would increase 
the overall benefit. The answer is multifaceted but appears to be cell and context 
dependent. For example, in a murine model of breast cancer, FAK kinase activity 
was determined to play a key role in tumorigenesis of luminal progenitor cell and 
in the maintenance of a luminal progenitor-derived stem cell-like population, 
while having no effects on tumors arising from other cell populations, suggesting 
that inhibitors of FAK kinase could be an effective single-agent therapy option for 
the subtype of breast cancer (184).  As shown in Chapter III, the majority of 
thyroid cancer cell lines are not sensitive to FAK kinase inhibitors, as they are 
more reliant on FAK scaffolding functions, and suggests that single-agent FAK 
kinase inhibitors are not the solution in this context. However, these studies 
relied on immuno-compromised mice models and recent literature demonstrated 
a significant role of the immune system in FAK-mediated tumorigenesis. In this 
study, FAK kinase activity in the cancer cells was responsible for inducing an 





and inducing regulatory T cells to inhibit cytotoxic CD8+ T cells, allowing tumor 
evasion, tolerance, and growth (42). Given the importance of FAK in regulating 
the immune system, future directions include using immune-competent models of 
thyroid tumorigenesis. Several genetically engineered mice strains already exist 
and mirror the characteristics and progression of advanced PTC and ATC 
observed in patients.  
While single-agent FAK inhibitors may be efficacious in certain settings, 
past pre-clinical and clinical data demonstrates that resistance to targeted 
therapy is inevitable. Therefore, I predict that the best approach for FAK 
inhibitors in the clinic will be as part of a combination therapy. Studies have 
demonstrated increased efficacy over single agent FAK inhibitors when 
combined with, for example, EGFR inhibitors or conventional chemotherapies 
(71,134,225,226). In Chapter IV, I demonstrated that cell lines insensitive to FAK 
kinase inhibition have increased sensitivity when also treated with a Src inhibitor, 
enhancing the efficacy of either single-agent alone. Others studies have also 
identified the combination of FAK and Src inhibition to increase anti-tumor 
processes and reduce drug resistance through adaptive plasticity (28,217,218). 
To continue my studies, this combination can be applied to more thyroid cancer 
cell lines, including those with RET/PTC rearrangements and PI3K mutations, to 
determine if this therapy would benefit patients regardless of mutational status. 
Combined FAK and Src inhibition must also be tested in vivo, in both an 
orthotopic and metastasis model, to define the effects of inhibition on tumor 





with inhibition, in vitro clonogenic assays and in vivo survival studies should be 
performed.  
Another unanswered question is what promotes the switch between FAK 
kinase and scaffolding functions? In our model, I propose that the switch from 
dependency on FAK scaffold to FAK kinase activity is dependent on Src activity, 
as demonstrated by our genetic, c-Src “gatekeeper” (drug-resistant mutant) 
studies (Figure 4.18). As Src is the predominant kinase in the FAK/Src complex, I 
hypothesize that inhibition of Src activity prompts the kinase activity of FAK to 
compensate, which makes FAK inhibitors more efficacious. However, other 
mechanisms are possible and warrant further examination. It has been shown 
that the functional results of FAK signaling are largely dependent on the 
mechanism of FAK activation; specific integrins and growth factor receptors elicit 
certain functional responses via FAK/Src signaling. As such, it is possible that 
integrin engagement and/or receptor activation could promote a switch in 
dependency from FAK scaffold to kinase. Using the dasatinib-resistant cells as a 
model of FAK functional switching, alterations in integrin engagement can be 
identified using flow cytometry and their function determined using blocking 
antibody assays. Activation of the integrins identified functionally important can 
be performed in a panel of thyroid cancer cells to determine if a switch between 
FAK scaffold and kinase activity occurs.   In addition, little is known about the 
mechanisms of FAK activation downstream of IL-1  and the IL-1 receptor. In our 
model of dasatinib-resistance, we show that IL-1  is elevated and contributes to 





function can be determined by assessing cell growth, survival, signaling, and 
invasion in response to combined FAK inhibitor and recombinant IL-1  in our 
panel of thyroid cancer cell lines.  
Of great importance, is identifying which tumors will be responsive to FAK-
directed therapy. As discussed above, FAK expression does not consistently 
correlate with prognosis across tumor types. Therefore, using FAK expression as 
a biomarker of response to FAK-targeted therapies is largely unreliable, 
complicated by the fact that FAK is rarely mutated in cancer. Recently, Merlin, a 
product of neurofibromatosis 2 (NF2) tumor suppressor gene, was identified as a 
biomarker of FAK kinase inhibitor sensitivity in mesothelioma, where intrinsic low 
Merlin expression correlated with PF-562,271 sensitivity (227,228). These 
preclinical studies paved the way for current clinical trials using PF-562,271 in 
patients with Merlin-negative mesotheliomas. As the only currently identified 
biomarker of response, we tested this in our panel of thyroid cancer cell lines but 
did not observe similar correlation between drug response and Merlin expression 
(not shown).  
Data from Chapter IV suggests that IL-1  regulates FAK signaling, and as 
such, may be a potential biomarker of response to FAK kinase inhibitors, 
however, additional experiments are required to fully make this claim. The 
concentration of IL-1  produced by the each of the cell lines in our panel of 
thyroid cancer cell lines can be quantified by ELISA assays, and correlated to the 
known sensitivity to FAK kinase inhibitors, both PF-562,271 and PF-573,228. In 





assays, to further define a role for IL-1  in mediating sensitivity to FAK inhibition. 
Of note, Merlin was found to be a biomarker of response only under in vitro 
anchorage-independent conditions, not adherent growth, and as such, it will be 
important to test these different assays. As a complimentary approach, IL-1  can 
be knocked down or knocked out via shRNA or CRISPR/Cas9 in cell lines with 
high levels of IL-1  expression, and used both in vitro and in vivo to further 
identify the role of IL-1  in response to FAK inhibitors. An independent study 
performing whole exome sequencing on a cohort of ATC and poorly-
differentiated thyroid cancer (PDTC) samples showed an increase in IL-1  
transcript in the ATC tumors compared to the PDTC tumors. The ATC tumors 
also had higher expression of a 62-gene macrophage signature, suggesting an 
increase in macrophage infiltration in ATC tumors compared to the PDTC tumors 
(229).  To corroborate these results and look at protein expression, a thyroid 
tumor microarray (TMA) can be stained to determine if IL-1  expression and 
macrophage infiltration is altered with tumor subtype, tumor progression, or 
prognosis. Expression of Cox-2 (PTGS2), a key target of IL-1 , can also be 
evaluated in these experiments, which would provide an additional therapeutic 
target in this pathway, through use of the FDA-approved, nonsteroidal anti-
inflammatory drug (NSAID), celecoxib. 
Given the critical link between FAK activation and integrin engagement, 
another potential biomarker of response to FAK inhibition is tumor stromal 
density. A recent study demonstrated FAK activity and signaling through integrin 





Carefully characterizing the tumor microenvironment of thyroid cancer, at 
baseline, and in response to various inhibitors, may provide insight into FAK 
inhibitor response. Tumor stromal density and activated integrins can be 
assessed by IHC, and future experiments would assess these markers in mouse 
models and the TMA.   
 As presented in the introduction, FAK can be localized to either the 
cytoplasm or the nucleus of a cell. In comparison to cytoplasmic FAK, very little is 
known about the nuclear functions of FAK, and even less is known about how 
nuclear FAK localization is regulated. Studies have shown that FAK is localized 
to the nucleus in response to cellular stress signals, cell detachment, and FAK 
inhibitors, such as PF-562,271 (127). I have preliminarily shown that treatment 
with PF-562,271 does not alter FAK localization in thyroid cancer cells, as 
analyzed by either western blot or immunofluorescence (data not shown). FAK 
localization does seem to be dependent, however, on Src activity, as treatment 
with dasatinib promotes FAK localization to the nucleus, which is mitigated by 
expression of a c-Src drug-resistant “gatekeeper” construct (data not shown). In 
addition, FAK localization appears to be heterogeneous as FAK can be observed 
via both Western blot and immunofluorescence in both the cytoplasmic and 
nuclear compartments at baseline (data not shown). My data in appendix A, 
performing IHC staining and analysis of a thyroid cancer TMA, demonstrates that 
FAK localization can be predominantly nuclear or cytoplasmic/membranous, or a 
combination of both. None of these localization types significantly correlated with 





we demonstrated in patient tumors, a wide range of FAK localization. While 
nuclear FAK is thought to function primarily through kinase-independent 
mechanisms, recent studies have shown kinase-dependent mechanisms that 
regulate gene expression. As such, the question to ask is, can FAK localization 
alone be a biomarker of response to FAK inhibition? The NES and NLS 
sequences of FAK have been identified and characterized, and can be mutated 
to keep FAK in or out of the nucleus, respectively. Future directions would be to 
test the sensitivity of these FAK-mutants to FAK and/or Src inhibitors. 
 
Significance and Implications 
 Together, the work described in this thesis represents an examination into 
the intricacy of FAK signaling through its dual roles as a kinase and scaffolding 
protein in order to improve targeted therapy options for advanced thyroid cancer 
patients, and other FAK-dependent tumors. Advanced thyroid cancers including 
PTC and especially ATC, have dismal prognoses which, even in this era of 
effective oncogene-driven targeted therapies, have seen very few therapeutic 
opportunities and almost no change in overall patient survival.  
 Genetically, advanced thyroid cancers have an overwhelming 
dysregulation of the MAPK and PI3K/AKT pathways, however targeted therapies 
inhibiting these pathways lack efficacy. As such, exploration into novel 
therapeutic targets for this patient population is warranted. The work in Chapter 
III presents evidence that FAK scaffolding/adaptor functions, not kinase activity, 





represents a novel and promising therapeutic target, as inhibitors of FAK protein-
protein interactions are coming to fruition.  
 As more targeted therapeutics find their way into the clinic, evidence is 
mounting that demonstrates only partial responses, and eventual relapse in 
patient populations, suggesting that drug efficacy is lacking and that mechanisms 
of resistance exists. There is little doubt that logical combination therapies will be 
required for continued clinical benefit of targeted therapy in cancer. Strong pre-
clinical data in thyroid and other cancer types demonstrates a role and potential 
therapeutic target in inhibiting FAK/Src signaling. My work presented in Chapter 
IV demonstrates that resistance to the single-agent Src inhibitor dasatinib occurs 
through cellular adaptive plasticity. The switch to a more invasive phenotype was 
promoted by a shift in dependency from FAK scaffold/adaptor functions, to FAK 
kinase activity. As such, combined FAK and Src inhibition increases the efficacy 
of either drug alone, and has great clinical potential as this combination may 
inhibit both the proliferative and invasive populations, which is of great 
importance to patients with advanced thyroid cancers that majorly succumb to 
their disease due to invasion and the development of distant metastases.  
Finally, the findings presented here demonstrate that FAK expression 
alone cannot be a biomarker of response to FAK kinase inhibitors and that future 
studies are required to more accurately identify which patients will benefit from 
FAK-directed therapies. However, inhibition of this target is reasonable and 
achievable in the proper context and drug-efficacy can be increased with rational, 





identifying drug treatments need to take into account the potential for phenotype 
switching and that both the proliferative and invasive populations should be 
targeted. This may ultimately require a change in how drug efficacy is studied, as 
current pre-clinical research does not typically evaluate the functional impacts of 
drug responses on invasion or changes in cellular phenotypes.  As a solution to 
this research challenge, a novel 3D hydrogel system was recently developed 
which simultaneously measures cellular metabolism and MMP activity in 
response to targeted therapy (231). Studying invasive outputs alongside 
traditional drug responses in pre-clinical tests will provide a better, well-informed 
selection of drugs for clinical trials, and a drop in the number of unwanted side 
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FAK Expression in a Thyroid Tumor Microarray 
 In collaboration with Dr. Sam Weisman at the University of British 
Columbia, we obtained a comprehensive, thyroid tissue tumor microarray (TMA). 
The TMA includes 500 thyroid tumors (1/2 malignant and 1/2 benign), and 31 
ATC samples with associated clinical data (tumor size, invasion, metastases). 
The TMA consists of duplicate 0.6mm diameter cores and, when possible, 
normal adjacent tissue. IHC staining for total FAK and pY861FAK was performed 
in collaboration with Dr. Scott Lucia and Elizabeth Smith in the UCD Histology 
Shared Resource Core and scored by Dr. Hilary Somerset, a pathologist at the 
University of Colorado. In addition to the TMA, ten PTC samples from the 
University of Colorado Shared Histology Core with associated tumor size, 
invasion and metastases information were stained and scored. Scoring included 
FAK localization (nuclear and membranous) and the staining intensity (0-3) and 
proportion (0-5) of each, as represented in table A.  Bioinformatics analysis was 
performed by Dr. Celia Sui in conjunction with Dr. Sam Weisman at the 
University of British Columbia. Analysis was performed based on the nuclear 
proportions for each tumor core. Analyzing across benign and cancer lesions 
(excluding ATC samples) demonstrated that the distribution of nuclear proportion 
scores was increased in the benign samples, and a significant difference 
(p≤0.05) was observed using the proportion score of 0-2 (≤10%) versus a score 
of 3-5 (>10%).  A Mann-Whitney U test for two independent samples was also 





benign and malignant samples. Expression of pY861FAK, represented by the 
nuclear proportion staining score, was decreased in cancer compared to benign 
samples. When analyzing between primary and nodal metastasis, the positive 
nuclear staining was unable to differentiate between the two. In addition, no 
association was observed between positive nuclear pY86FAK staining and tumor 
size, patient age, extrathyroidal extension, vascular invasion, of the ATC 
subtype. Analysis regarding nuclear intensity scores, and membranous 
proportion and intensity scores have yet to be performed.  After comprehensive 
optimization for total FAK, we were unable to obtain specific staining, most likely 
due to the multiple proteins recognized by this antibody, as shown by Western 
blot analysis.  Thus, future studies will be needed to obtain specific total FAK 












Characterization of Dasatinib-Resistant Tumors 
 Given the changes in phenotype observed in vitro with dasatinib-
resistance (Chapter IV), we sought to evaluate the effects of acquired resistance 
to Src inhibition in vivo, using both a BRAF- and RAS-mutant models of thyroid 
cancer. For the BRAF-mutant model, BCPAP control and DasRes cells were 
engineered to express GFP-luciferase and were injected orthotopically into the 
right thyroid gland of athymic nude mice, as previously described (141,213).   
Bioluminescent imaging showed a significant, 28-fold increase in growth over 
time in the BCPAP DasRes tumors compared to the control tumors (Figure B.1A) 
(Control: 4.50x108 ± 1.16 p/s; DasRes: 126.5x108 ± 42.67 p/s; p≤0.001, ANOVA). 
Likewise, the final tumor volume of the DasRes tumors were significantly greater 
than their control counterparts (Figure B.1B) (4.2-fold, p≤0.05).  
Figure B.1: BRAF-mutant dasatinib-resistant tumors are more aggressive 
in vivo. (A) Mice were injected orthotopically with BCPAP control and DasRes 
cells. Tumor growth overtime was observed via bioluminescence signaling. 
Results shown are mean bioluminescence signal (photons/sec) per group ± 
SEM at the indicated time points. (B) BCPAP tumors were collected at day 30 
and size was measured via calipers. Final tumor volumes were calculated. 






An increase in ppERK was observed in the DasRes tumors compared to control 
tumors, suggesting a reactivation of the MAPK pathway, which validates our in 
vitro data (140).  In accordance with our in vitro data, no change in proliferation 
was observed between the BCPAP DasRes and control tumors, as identified with 
Ki67 staining (Figure B.2A). Angiogenesis, measured by IHC staining for CD34 
on endothelial cells, was not altered between groups (Figure B.2B).   In addition, 
the macrophage population, marked by F4/80 IHC staining, in the tumors was not 
different between groups (Figure B.2C). Tumors for these studies were taken at 
the end of the experiment, when mice reach moribund criteria. As such, future 
studies can assess these markers at different time points, to better evaluate the 
contribution of these factors to tumorigenesis and progression.   
 
We next evaluated the RAS-mutant model of thyroid cancer using the 
Cal62 control and DasRes cells in vivo. These cells were injected into the flank of 
athymic nude mice, as they do not take in the orthotopic location. Both in vivo 
and final tumor volumes show a significant increase in the DasRes tumors 
Figure B.2: Aggressive phenotypes are similar in BRAF-mutant control 
and dasatinib-resistant tumors. IHC staining for (A) Ki67, (B) CD34, and (C) 
F4/80 was performed on sections of each tumor and scored by a pathologist or 






compared to the control tumors. In vivo tumor volumes at Day 35 for the control 
and DasRes tumors were 6.20 ± 17.98 mm3 and 432.9 ± 61.28 mm3, respectively 
(Figure B.3A) (6.6-fold; p≤0.0001, ANOVA). The DasRes tumors were, on 
average, 8.85-fold larger than the control tumors (Figure B.3B) (Control: 60.38 ± 
16.22 mm3; DasRes: 534.2 ± 73.28 mm3; p≤0.001).   
 
Interestingly, and in contrast to our in vitro data, we observed a significant 
increase in proliferation of the Cal62 DasRes tumors compared to their control 
counterparts (p≤0.01; Figure B.4A). Furthermore, tumor angiogenesis was 
significantly increased in the DasRes group (p≤0.0; Figure B.4B). In addition, the 
macrophage population in the DasRes tumors was significantly decreased 
compared to the control tumor group (p≤0.0001; Figure B.4C). 
Figure B.3: Dasatinib-resistant RAS-mutant tumors are more aggressive 
in vivo than their control counterparts. Mice were injected into the flanks with 
Cal62 control and DasRes cells. (A) Tumor growth overtime was assessed by 
measuring tumors in vivo using calipers. Results shown are mean tumor 
volumes (mm3) per group ± SEM at the indicated time points. (B) Cal62 tumors 
were collected at day 35 and size was measured via calipers. Final tumor 






Given the changes observed in vitro with MMP production and activity, 
and knowing that alterations in ECM synthesis, density, and degradation can 
promote aggressive cancer phenotypes (232), we evaluated the ECM protein 
collagen in the tumors using second harmonic generation (SHG) imaging. Both 
the BRAF- and RAS-mutant DasRes tumors had significantly less collagen 
deposition, quantified by SHG signal intensity, than the tumors formed from the 
control cell lines (BCPAP: p≤0.01; Cal62: p≤0.05; Figure B.5A and B). Other 
measures of collagen using SHG include identifying the length and density of 
individual collagen fibers, and evaluating the orientation of collagen fibers 
compared to the invasive front of the tumor. These SHG measures have been 
shown to correlate with aggressive phenotypes in breast cancer and melanoma, 
however, additional studies and analyses are necessary to fully define these 
measures in our models.   
Figure B.4: Aggressive phenotypes are increased in RAS-mutant 
dasatinib-resistant tumors. IHC staining for (A) Ki67, (B) CD34, and (C) F4/80 
was performed on sections of each tumor and scored by a pathologist or the 










Figure B.5: Dasatinib-resistant tumors have deceased collagen 
deposition. SHG imaging was performed on (A) BCPAP and (B) Cal62 control 
and DasRes tumors. Representative images of SHG and two-photon excited 
fluorescence (TPEF) signals are shown (bottom). SHG signal intensity for each 
tumor was quantified. Results shown are mean signal intensity (arbitrary units) 
± SEM for each tumor group (top).  
 
